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Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that mediates 
interactions between the extracellular matrix and intracellular signaling pathways critical in 
promoting numerous cellular functions including adhesion, proliferation, survival and 
migration. Most FAK functions result from phosphorylation by Src family kinases, which 
trigger numerous signaling cascades. Overexpression of FAK is associated with metastasis in 
many solid tumors, including prostate cancer. Hence, understanding the mechanisms by which 
FAK is regulated in prostate cancer will better elucidate its role in prostate cancer metastasis. 
Work in this dissertation tested the hypothesis that altered phosphorylation of FAK is critical 
for cell migration and promotion of prostate cancer metastasis. 
To address the hypothesis, I developed highly migratory variants of prostate cancer 
cells. These cells were increased in invasion, decreased in adhesion and had increased 
metastatic potential. A hallmark of the migratory variants was increased phosphorylation of 
FAK Y861. To examine the mechanism for this increased phosphorylation, expression and 
activity of Src family members were assessed. The migratory variants were increased in 
expression and total activity of the SFK, Yes, but no other members of the Src family kinases. 
I demonstrated that Yes was specifically responsible for the phosphorylation of FAK Y861 
using both prostate tumor cells and src-/-, yes-/-, fyn-/- mouse embryo fibroblasts and that 
vi 
 
increased Yes expression was directly responsible for increased migration of the selected 
migratory variants. Using shRNA plasmids directing knockdown of Yes, I further 
demonstrated that silencing Yes inhibits prostate cancer lymph node metastasis in vivo in an 
orthotopic model of prostate cancer tumor growth and metastasis. Furthermore, in human 
specimens, I demonstrated that Yes expression and phosphorylation of FAK Y861 was 
increased in lymph node metastases relative to primary tumors, with the latter correlating with 
decreased patient survival.  
In summary, I have identified novel roles for Yes in selectively phosphorylating FAK 
relative to other SFKs, resulting in increased migration and metastasis of prostate cancer cells. 
Therefore, increased expression of phosphorylated FAK at tyrosine 861 and Yes kinase may 
be predictive markers for prostate cancer progression.  
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Introduction 
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Prostate Cancer (PCa) is the most commonly diagnosed form of cancer and the second 
leading cause of death due to cancer in men in the United States [1]. According to The American 
Cancer Society, there will be 233,000 estimated new cases of prostate cancer and 29,400 men 
are expected to die due to the disease in 2014. Localized disease is almost always curable, with 
a survival five-year rate exceeding 99% [2]. Hence, for patients with early stage localized 
disease, “active surveillance” is often recommended [3]. Nevertheless, many patients, even 
those diagnosed at a relatively early stage will choose radical prostatectomy, proton therapy or 
external radiation beam therapy because prediction of prognosis of prostate cancer is still 
unclear [4-6]. Additionally, many patients with early stage prostate cancer may choose to opt 
for androgen-ablation strategies as inhibition of the levels of androgens by androgen-ablation 
therapy leads to anti-tumor effects in early stage prostate cancer [6].  
Prostate cancer, in its early stages, has few overt symptoms, hence, without performing 
a biopsy, diagnosis of prostate cancer in patients is challenging. Currently the biomarker used 
by some clinicians to guide diagnosis of prostate cancer is elevated levels of prostate-specific 
antigen (PSA) [7]. Presence of high serum levels of PSA (<4.0ng/mL) indicates, in some men, 
increased probability of having prostate cancer [8]. However, PSA is secreted by both normal 
and tumor prostate epithelial cells and increase in PSA concentration often occurs due to other 
factors such as increasing age and inflammation of the prostate [9]. On the contrary, low levels 
of PSA do not always indicate absence of prostate cancer [7]. The difficulty with PSA as a 
predictor of prostate cancer is illustrated by of two recent clinical trials by Andriole et al., 2009 
and Schröer et al. 2009. These trials have resulted in a controversial recommendation by the 
United States Preventive Services Task Force (USPSTF) against prostate cancer screening 
using PSA. However, regardless of the recommendation, The American Cancer Society 
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recommends that men at age 50 should discuss the benefits and limitations of PSA testing with 
their health care providers. High concentrations of PSA often lead to biopsies, which are more 
diagnostic.   
If patient is biopsied, staging of the cancer is performed by the five-tier Gleason grading 
system [10]. The grading consists of the sum of two scores from well-differentiated pattern to 
most poorly differentiated pattern ranging 1-5, necessary because of the heterogeneity of the 
tumor. The most prevalent pattern (observed in more than 50% of the tumor) is the primary 
score and the second most prevalent pattern (observed in less than 50% but more than 5% of 
the tumor) is the secondary score ranging from 1-5. A low Gleason score of 2-6 has a five-year 
recurrence-free survival risk of 94.6%. As the Gleason score increases to 7 (3+4 or 4+3), 
recurrence-free survival risk drops to 82.7% and 65.5% respectively. Gleason score of >7 is 
considered high-grade cancer with the highest scores 9-10. Patients with Gleason scores of 9 or 
10 have the five-year recurrence free survival of 34.5% [11]. While treatment for patients with 
Gleason scores >7 is always recommended, which lower grade tumors will progress and which 
may never progress during a man’s lifetime is not clear. Thus developing better biomarkers to 
predict prostate cancer progression is of high priority. Considerable focus has been made on 
whole genome sequencing, SNP analysis, etc., to develop novel biomarkers, but these 
approaches have not led to an easily assayed serum marker.   
Deaths from prostate cancer primarily arise from metastasis that can occur to several 
organs such as lungs, liver, brain and in 80% of prostate cancer cases, to the bone [12]. The 
five-year survival rate of metastatic prostate cancer drops drastically to 31% from 99% [2], as 
current therapeutic regimens have little effect on improving long-term survival of patients 
afflicted with metastasis [13]. Therefore, gaining a better understanding of the mechanisms by 
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which prostate cancer metastasizes is critical to developing novel therapies for this late-stage 
disease. 
Some progress has been made in treatment of metastatic disease. In the last three years, 
several drugs that have been approved by the Food and Drug Administration (FDA) for 
treatment of metastatic prostate cancer, including Abiraterone Acetate [14], Enzalutamide [15] 
and Bicalutamide [16]. These drugs have been based on numerous studies that indicate that 
even late castrate-resistant metastatic disease are still “driven” by the androgen/AR pathways 
[17], and these drugs inhibit AR-driven genes by different mechanisms. More recently, 
advances in immunotherapy have led to considerable promise for the treatment of several 
tumors, including prostate cancer [18]. These include FDA approval of Siuleucel-T and 
Ipilimumab [2, 19-21]. These drugs have improved patient survival; however, few if any 
patients are cured by these new agents [22]. A major cause of short survival is development of 
resistance, in which compensatory signaling pathways still drive metastatic growth [23-25]. 
Hence, understanding both the mechanisms of resistance and mechanisms that lead to 
metastasis may provide new biomarkers and therapeutic targets. These advances in therapy may 
come from understanding the genetics and epigenetics of prostate cancer (discussed in the next 
sections), along with understanding the alterations in the androgen/AR pathway that drive 
prostate cancer progression (discussed later).  
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Genetic alterations in prostate cancer 
Genetic changes in prostate cancer are fewer than in many other solid tumors, although 
many have been identified as summarized in a recent review by Boyd et al.[26]. Through several 
strategies, gains and losses of chromosomes have been observed. Gain of chromosome 8q is 
observed in 34% of prostate cancer cases and losses at chromosomes 3p, 8p, 10q, 13q, and 17p 
are observed in 30-50 % of prostate cancer cases [27-29]. Some of the key regulatory genes that 
are located within this region, including NKX3.1 at 8p21, PTEN at 10q23, MYC at 8q24, and 
fusion of TMPRSS2 and ERG both located at 21q22.3 to form TMPRSS2:ERG [30]. Some of 
their roles in prostate cancer initiation and progression will be discussed below briefly.   
Loss of NKX3.1 
 NKX3.1 is a tumor suppressor gene and a transcription factor that is a critical regulator 
of prostate epithelial differentiation. It is located on chromosome 8p21.2 NKX3.1 shows loss of 
heterozygosity (LOH) in 20% of high-grade intra epithelial neoplasia (PIN), a precursor to 
prostate adenocarcinoma and 78% of metastases [31]. Evidence that it is important in prostate 
cancer progression has been developed from genetically engineered mouse models that indicate 
that deletion of a single NKX3.1 allele or complete knockout results in hyperplasia or dysplasia 
in prostate cancer mouse models [32, 33]. Studies have indicated that prostate glands of NKX3.1 
null mutant transgenic mice resemble histopathological alterations of human PIN [34-36] and 
NXX3.1 null mice have the characteristics of early stages of prostate cancer [37]. Hence, these 
findings strongly suggest NKX3.1 is a tumor suppressor gene that prevents prostate cancer 
initiation. 
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Loss of PTEN 
Phosphatase and tensin homolog (PTEN) is a lipid-phosphatase that de-phosphorylates 
the 3 position of the inositol ring of PtdIns (3,4,5)P3 and thus inactivates several pathways, one 
of the major ones is the protein kinase B/AKT kinase pathway, critical in survival and growth 
of prostate cancer [38]. It was identified as a tumor suppressor gene and is located on 
chromosome10 q23 normal epithelial cells [38-41]. PTEN undergoes allelic loss in observed in 
20-30% prostate cancers[42] and epigenetic silencing of PTEN is observed in 60% prostate 
cancers[40]. Studies with genetically engineered mice with knock out of PTEN have indicated 
that deletion of PTEN in mice causes PIN, followed by progression to invasive adenocarcinoma 
[43]. Additionally, loss of PTEN also promotes progression to castration-resistant prostate 
cancer [44]. These data indicate that PTEN loss promotes prostate cancer progression. 
TMPRSS2:ERG 
TMPRSS2:ERG is a fusion gene consisting of the TMPRSS2 located on 21q22.3, 
regulated by androgens, which can be fused to the transcription factor ERG located on 
chromosome 21q22.2 from the ETS family [45]. This fusion gene is found in 50% of prostate 
cancers, implicating that presence of TMPRSS2:ERG fusion can be a critical event in prostate 
cancer progression leading to androgen-regulated high expression of a transcriptionally active, 
N-terminal truncated ERG protein that contributes to prostate cancer development and 
progression [46]. Transgenic expression of this fusion gene in mouse models results in PIN 
lesions, loss of PTEN and activation of the PI3K pathway leading to prostate cancer initiation 
[47]. Together, these data indicate that TMPRSS2:ERG fusion is critical in prostate cancer 
initiation and progression. 
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MYC upregulation 
MYC is a transcription factor that regulates variety of cellular processes [48]. It is located 
on chromosome 18q24 which is amplified ~40% of the primary tumors and ~90% in prostate 
cancer metastases [49]. Studies using genetically engineered mouse models indicate that 
overexpression of MYC in the prostate of transgenic mice induces formation of PIN, leading to 
invasive prostate adenocarcinoma[50]. Transgenic mice overexpressing MYC when crossbred 
with PTEN-null mice developed high-grade PIN, which progressed to prostate cancer [51]. 
Collectively these data indicate that upregulation of MYC is associated with prostate cancer 
initiation and progression. In summary, while these genetic alterations may lead to biomarkers 
important in prostate cancer initiation or progression, none to date has resulted in targeted 
therapies. 
Androgen signaling in prostate cancer progression 
Although genetic alterations are required for prostate cell transformation and cancer 
initiation, AR signaling is the driver of prostate cancer at early stages. Binding of androgen to 
AR leads to formation of an androgen/AR receptor complex that translocates to the nucleus and 
binds to AR-responsive elements, and orchestrates transcription of androgen-regulated genes 
[52]. Activation of androgen-regulated genes promotes cell survival, proliferation and 
prevention of apoptosis of cancer cells [53]. Hence, inhibition of the levels of androgens by 
androgen-ablation therapy leads to anti-tumor effects in early stage prostate cancer also known 
as the “endocrine-phase” of prostate cancer [54].  
As prostate cancer progresses under androgen-ablation selection pressure, the tumor 
evolves and escapes dependence on androgen entering the “paracrine-phase” [54]. In this phase, 
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the disease is not only driven by androgens but also numerous stimuli/molecules secreted from 
the microenvironment [54]. Hence, the “paracrine-phase” of tumor development involves both 
the tumor and the microenvironment to promote metastasis. Collectively, the “endocrine-phase” 
and the “paracrine-phase” lead to development of prostate cancer metastasis, which does not 
respond to chemotherapeutics leading to mortality of patients. Therefore, in the next section, I 
will briefly describe the metastatic process in prostate cancer and the selected signaling 
pathways that are associated with metastasis relevant to my thesis work that may lead to novel 
therapeutic approaches. 
Prostate cancer metastasis  
As the vast majority of deaths due to prostate cancer result from metastases, mostly to 
the bone but also to the viscera and a better understanding of the metastatic process is required 
to develop novel therapies that will prolong survival. The metastatic process is extremely 
inefficient but selective, with less than 0.1% of the cells that enter the circulation, surviving to 
form metastasis at the distant sites [55]. The classical model of metastasis, the “seed and soil” 
hypothesis was first proposed by Stephen Paget in 1889, which states that tumor cells (seeds) 
only metastasize to specific organs (soil) that facilitate their growth [56]. Work that is much 
more recent has led to the understanding that the tumor microenvironment at the metastatic site 
plays an important role in the development of the “soil” that facilitates the process of metastasis. 
Classically, as defined by Fidler et al.[57], the metastatic process has been described as 
a series of individual but linked steps including angiogenesis, migration, invasion, intravasation, 
circulation, extravasation and finally, colonization in distant organs [58]. Several models have 
been described to understand the progression of these steps. One model is the “linear 
progression model” that states that cancer cells pass through multiple successive rounds of 
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mutations to select for cells with competitive fitness in the context of the primary tumor to go 
through above mentioned steps in metastasis [59]. The tumor cells that can survive and 
proliferate at a competitive rate, expand and subsequently leave the primary tumor sites to 
colonize on the secondary sites [59]. However, dissemination of tumor cells can occur early 
(when the primary tumor is small). The second model is the “parallel progression model”, that 
states that metastasis can occur in parallel to the development of the primary tumor and this 
model does not consider the occurrence of dissemination of cells as a later phenomenon after 
development of primary tumor [60]. Moreover, dissemination of cells can occur during the 
development of primary tumor as the cells adapt to the tumor microenvironment [59].  
In spite of the presence of the different models that define cancer progression, a critical 
process that facilitates metastasis in both these above-described models is bidirectional 
interactions between tumor cells and microenvironment, occurring both at the primary and 
metastatic sites. At the primary site, one of the adaptations is epithelial to mesenchymal 
transition (EMT), which allows cells to acquire a more mesenchymal phenotype, increasing 
their abilities to migrate and invade through the ECM. However, the cancer cells later revert to 
the mesenchymal phenotype by mesenchymal to epithelial transition (MET) allowing adherence 
to ECM and growth at the metastatic site. This ability of cancer cells to switch between different 
phenotypes through EMT and MET is a feature of “epithelial plasticity” [61, 62].  
A recent study demonstrated that switching between different modes of cell migration 
is required for epithelial plasticity and metastasis [63], indicating the role of  migration of cells 
in metastasis. In prostate cancer, a number of studies have demonstrated a strong correlation  
between increased migration of prostate cancer cells and metastasis [64-66]. However, the 
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molecular mechanisms that regulate the process of migration remain unclear. Hence, a principal 
focus of this thesis was to understand the role of migration in metastasis of prostate cancer. 
Migration signaling in prostate cancer 
 While there multiple modes of migration, classified as amoeboid migration, 
mesenchymal migration, multicellular streaming and collective migration [67], the underlying 
process in all the modes of migration results in changes in cytoskeletal dynamics. These are 
highly complex processes that involve many signaling pathways [68].   
Relevant to my work, Focal Adhesion Kinase (FAK) is a critical mediator of migration 
signaling. FAK is a non-receptor tyrosine kinase that localizes to focal adhesions, which 
mediate interactions between the extracellular matrix and intracellular signaling through 
integrin activation upon cell attachment to the extracellular matrix [69]. The role of FAK in 
migration is demonstrated in FAK-null mouse embryonic fibroblasts, which form irregular focal 
adhesion complexes in which FAK turnover does not occur and cells do not migrate; the first 
demonstration that FAK turnover was essential to migration [70]. The next section of this thesis 
briefly describes the structure and activation of FAK followed by the role of FAK in the process 
of cell migration.   
Focal adhesion kinase (FAK) 
Structure of FAK 
FAK is a 128 KDa non-receptor tyrosine kinase that, as described above, localizes to 
focal adhesions. X-ray crystallography has revealed that FAK consists of an N-terminal four-
point-one ezrin radixin moesin (FERM) domain, a central kinase domain, proline-rich regions, 
- 11 - 
 
and a C-terminal focal-adhesion targeting (FAT) domain (Figure 1) [71]. These domains are 
arranged as a tripartite globular structure with the FERM domain organized in a compact 
cloverleaf conformation connected by an unstructured linker to the catalytic domain, which in 
turn is connected to a four-helix bundle structure of FAT domain by an unfolded proline-rich 
region (Figure 2). Each of these domains and their functions are briefly described below. 
N-Terminal domain  
The N-terminal is also known as the FERM domain that has three lobes, the F1, F2 and 
F3 subdomains. The F1 subdomain consists of a five-strand β sheet capped by and α-helix. The 
F2 subdomain is entirely α-helical with a core similar to acyl-CoA-binding protein. This region 
of the protein docks with the catalytic domain of the FAK itself and forms the auto-inhibited 
conformation. The F3 subdomain is a β-sandwich capped by a C-terminal α-helix. The linker 
between the FERM and the kinase domain consists of an anti-parallel β-sheet that binds on a 
groove on the F3 subdomain. Two important features of the linker are tyrosine 397, the major 
autophosphorylation site and the nearby “PxxP” motif that acts as and SH3-domain binding site 
[72] as shown in Figure 2. The FERM domain facilitates interaction of FAK with other receptor 
tyrosine kinases such as MET, EGFR, PDGFR and also some integrins [73]. These interactions 
are required to activate signaling cascades that promote migration, as well as invasion, survival, 
proliferation, adhesion and anti-apoptosis[73]. 
Kinase domain 
This is the primordial conserved domain related to all tyrosine kinases. The crystal 
structure of FAK kinase domain reveals a bilobed structure with the N-terminal lobe containing 
a single α-helix with a five-stranded β-sheet and the larger C-terminal lobe that is mostly α-
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helical [72]. In the kinase domain itself are three tyrosine phosphorylation sites (Y407, Y576 
and Y577). Phosphorylation of these sites results in formation of a β hairpin loop confirmation, 
as observed in other active kinases [74]. 
C-Terminal domain  
The C-terminal of FAK contains the focal adhesion targeting (FAT) domain contains 
four amphipathic α-helices that assemble into an antiparallel four helix bundle. The FAT 
domain also consists of two hydrophobic patches that bind to the FAK-associated proteins 
containing the leucine-rich (LD) domain. The α- helix 1 of the FAT domain contains tyrosine 
861 and tyrosine 925 [75]. Specific functions of the C-terminal domain of FAK include 
association of the FAT domain to integrins and localization of FAK to focal adhesion 
complexes, which is required for migration of cells [72, 75]. Additionally, tyrosine 861 and 
tyrosine 925 upon phosphorylation by Src family kinases (SFKs) recruit Grb2 via the Grb2 SH2 
domain, leading to activation of the Ras/Raf/MAPK/ERK proliferation pathway.  
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Figure 1: Structure of FAK. FAK consists of an N-terminal FERM domain, a C-terminal 
FAT domain and a kinase domain. Multiple tyrosine phosphorylation sites present on FAK 
include Y397, Y401, Y576, Y577, Y861 and Y925. FAK contains three proline-rich regions 
PRR1, PRR2 and PRR3 that bind to SH3 domain containing proteins. 
From Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: In command and 
control of cell motility. Nat Rev Mol Cell Biol 6: 56-58. Reproduced with permission. 
 
  
- 14 - 
 
  
      
 
Figure 2: Crystal structure of FAK A. Three lobes FERM domain with subdomains F1 
(Red), F2 (Blue) and F3 (Green) B. Kinase domain with a small N-terminal lobe with single α-
helix and β strands C. FAT domain of FAK with the containing four-helix bundle (colors 
indicate different helices) D. Structure of auto-inhibited FAK FERM domain, the FERM 
domain is indicated blue, the linker segment is green and the kinase domain is yellow. Tyrosine 
397 autophosphorylation residue is on the linker segment represented by sticks colored in red. 
Association of p130Cas to the tyrosine 861 and tyrosine 925 leads to recruitment of Crk/DOCK 
complexes, that regulate signaling pathways involved in migration of cells [76-78].From Hall 
JE, Fu W, Schaller MD. (2011) Focal Adhesion Kinase: Exploring FAK Structure to Gain 
Insight into Function. Int Rev Cell Mol Biol. 288-185-225. Reproduced with permission. 
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Activation and regulation of FAK 
As stated above, FAK can be activated by multiple mechanisms, principally including 
integrin clustering or growth factor receptor activation [72]. FAK activation occurs through 
sequential steps starting with release of the FERM-kinase domain from the intramolecular 
interaction after binding to a heterologous FERM binding partner. After the FERM domain is 
released, activation of FAK occurs upon autophosphorylation of tyrosine 397 [79]. 
Phosphorylated tyrosine 397 then binds to SH2-domain containing proteins including Src 
family kinases (SFKs), PI3-Kinase, PLCγ, SOCS, Grb7, Shc and p120RasGAP. SFK binding 
to pFAK Y397 (through the SFK SH-2 domain) leads to activation of the interacting proteins 
(Figure 4), and phosphorylating each of the other tyrosine phosphorylation sites on FAK, 
specifically Y577, Y576, Y407, Y861 and Y925 [80]. As stated above, phosphorylation of FAK 
Y576 and FAK Y577 is required for complete activation of the FAK kinase, and the activated 
FAK kinase domain adopts a conformation that cannot be inhibited by FERM-mediated 
intramolecular interactions, as the phosphorylated activation loop precludes the inhibitory 
docking of the FERM domain (Figure 2) [80]. 
Role of FAK and cell migration   
For migration to occur, the leading edge of the cells must attach to the ECM, a process 
that results in formation of focal contacts [81]. During the formation of focal contacts, FAK is 
recruited to the focal contacts and associates with the Arp2/3 complex to promote actin 
polymerization and causes cell spreading [82]. The cell then elongates to form cell protrusions 
called pseudopods, which result in distinct polarity differences between the cell “front” and 
“rear” as shown in Figure 4 [83]. The cell protrusions that associate with ECM are called 
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lamelipodia, which are broad, flat sheet like structures and filopidia, which are thin, elongated, 
needle-like structures [84]. In the next stage of migration, the growing protrusions containing 
integrins bind to the ECM resulting in integrin clustering leading to autophosphorylation of 
FAK Y397 and subsequently phosphorylation of FAK at Y401, Y576, Y577, Y861 and Y925 
[85]. Specific to migration signaling, phosphorylation of FAK Y397 leads to recruitment of PI 
3-kinase and activation of Rac GTPases required for lamelipodia formation and migration 
(Figure 5) [86]. Phosphorylation of FAK Y 861 and FAK Y 925 leads to recruitment of p130Cas 
and formation of complexes with Crk/DOCK 180 and activation of Rac GTPases, which are 
also essential in lamelipodia formation, and cell migration [87]. Simultaneously, FAK 
phosphorylates both the guanine nucleotide exchange factor (GEF), that activate Rho proteins 
and GTPase activating protein (GAP) that deactivate Rho proteins necessary to generate 
contractile forces and induce cell polarity required for migration [88]. In the final stages of 
migration, tyrosine phosphorylation of FAK results in disassembly of focal adhesion complexes 
[89], detachment of the trailing edge leading to turnover of FAK and forward movement of the 
cell.  
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Figure 3: Activation of FAK. The FERM domain directly binds to the kinase C-lobe when 
FAK is auto-inhibited, impeding access to the FAK active site and protecting FAK activation 
loop from phosphorylation by SFKs. Binding of a protein or a lipid-partner to the FAK FERM 
domain leads to conformational change in FAK and release of the auto-inhibited “closed” state. 
This conformational change allows binding of SFKs leading to tyrosine phosphorylation of 
FAK and increases its kinase activity. 
From Frame MC, Patel H, Serrels B, Leitha D, Eck MJ (2010). The FERM domain: organizing 
the structure and function of FAK. Nat Rev Mol Cell Biol.11 (11):802-14. Reproduced with 
permission. 
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Figure 4: Cell migration. Directed cell migration occurs upon coordinated formation of focal 
adhesion complexes in the leading edge of the cell followed by simultaneous detachment of the 
focal complexes in the trailing edge of the cell. Several molecules like integrins, FAK, Rho/Rac 
GTPases are required for the cell to migrate. 
From Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: In command and 
control of cell motility. Nat Rev Mol Cell Biol 6: 56-58. Reproduced with permission. 
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FAK in prostate cancer progression 
FAK is overexpressed in many solid tumors; including prostate cancer and increased 
FAK expression is associated with prostate cancer progression [90, 91]. However, the existing 
studies on FAK overexpression and prostate cancer are correlative; and whether overexpression 
of FAK plays a casual role of FAK in prostate cancer progression still remains to be established 
[92].  
In addition to lack of knowledge about the role of FAK overexpression in mediating 
prostate cancer metastasis, considerable information is lacking with respect to potential roles of 
differential phosphorylation of different FAK tyrosine residues. While FAK phosphorylation 
and the signaling pathways mediating proteins interacting with these tyrosine residues have 
been well described, few studies have addressed whether altered phosphorylation at one or more 
sites contribute to tumorigenicity and progression of prostate cancer. Recent work from Slack 
JK et al. has indicated that phosphorylation of FAK Y861 is associated with more migratory 
prostate cancer cells [78]. Additionally, phosphorylation of FAK Y861 is also associated with 
oncogenic transformation of fibroblasts [93]. However, these observations are only 
associations, and mechanisms of increased phosphorylation of specific FAK tyrosine 
phosphorylation sites and their biological relevance is unclear. Hence, this thesis focused on the 
unanswered questions in FAK regulation that might mediate biological properties of prostate 
cancer progression. 
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Figure 5: FAK is the central mediator of migration pathway. Multiple molecular pathways 
regulate migration of cells including integrins and growth factor receptors and non-receptor 
tyrosine kinases. The FAK/SFK signaling pathway is the central mediator of migration 
signaling. Additional pathways that regulate migration, survival and proliferation of cells 
include, PI3-K /AKT and the Ras/Raf/MEK/ERK pathway.  
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Src family kinases- Structure, Activation and Function 
As discussed in the previous sections, after the initial autophosphorylation of FAK, 
SFKs are required for the additional phosphorylations. These phosphorylations are critical to 
all FAK functions, including migration, invasion, angiogenesis, cell survival, cell proliferation, 
cell cycle regulation, epithelial to mesenchymal transition and resistance to anoikis [94-99]. As 
SFKs are required for FAK-mediated migration, it is not surprising that Src family members 
themselves are also associated with migration, as activation of Src increases migration [100-
103] and src-/- cells are impaired in migration [104]. Therefore, understanding the relationship 
among SFKs and FAK is critical in understanding the migration process.  
Structure and activation of the SFK family 
SFKs are a group of nine structurally highly related non-receptor tyrosine kinases 
consisting of Src, Yes, Fyn, Lyn, Lck, Blk, Fgr, Yrk and Hck [100]. SFKs mediate signals from 
numerous cellular stimuli including integrins, receptor tyrosine kinases, cytokine receptors, ion 
channels, G-protein coupled receptors, polypeptides, and hormones that activate downstream 
signaling pathways that regulate numerous cellular functions. To better understand the role of 
SFKs in prostate cancer migration, a brief introduction to the structure and activation of SFKs 
are described below. 
The structure of SFKs is composed of an N-terminal membrane-targeting region that is 
myristoylated. Many Src family kinases (the exception being Src itself) are also palmitoylated 
at the N-terminal glycine residue. The Src homology-4 (SH-4) domain residues at the amino 
terminus function for membrane localization; Src homology-3 (SH3) domain involved in 
intermolecular binding by recognizing prolines in the Pro-xx-Pro motif of the substrates; the 
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Src homology-2 (SH2) domain interacts with numerous phospho-tyrosine containing proteins, 
including its own C-terminal tyrosine 530 residue that leads to a closed conformation (see 
below); the kinase domain or Src homology-1 (SH-1) is the primordial tyrosine kinase domain 
[105].   
Activation of SFKs occur when the SFK-SH2 domain of FAK has higher affinity to the 
phospho-tyrosine domains of numerous factors that it can interact with relative to the negative-
regulatory tyrosine 530 (human nomenclature) residue on its own SH2 domain [100]. Upon 
binding of the activated growth factor receptors to SFK-SH2 domain, a conformational change 
occurs that increases the accessibility to phosphatases that dephosphorylate the C-terminal 
phospho-tyrosine residue (tyrosine 530 in human Src). Once in the “open” conformation, 
autophosphorylation of the tyrosine 419 residue (human Src) occurs leading to “complete” 
catalytic activation of Src (Figure 6) [106]. 
As numerous proteins that interact with SFKs are aberrantly expressed or activated in 
several solid and hematological tumors [107-110], SFKs themselves are also frequently 
activated as well [110, 111]. 
SFKs in Prostate cancer 
SFKs have aberrantly increased activity in prostate cancer cells and they have various 
functions in prostate cancer progression as described above. Additionally, different members of 
the SFK family are also suggested to play important roles in prostate cancer progression. Jensen 
AR et al., demonstrated that Fyn plays important roles in prostate cancer cell growth and 
chemotaxis, required for metastasis [112]. Additionally, Lyn kinase regulates androgen 
expression and activity in castrate-resistant prostate cancer and mice in which Lyn is 
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functionally deleted showed abnormal morphogenesis of the prostate gland [113-115]. 
Interestingly, a recent study by Cai H et al. indicates that ectopic expression of Src, Fyn and 
Lyn kinase in primary prostate cancer cells isolated from Src−/−Fyn+/−, Fyn+/−, Fyn−/−, or 
Lyn−/− knockout mice have different transformation capacities, with Src inducing the strongest 
oncogenic phenotype, followed by Fyn and then Lyn [116]. Regenerated tissue from Lyn-/- 
epithelium on transformation displayed neoplastic growth, whereas transformation of tissues 
from Fyn-/- epithelium exhibited PIN lesions. In contrast, transformation of tissue from 
Src−/−Fyn+/− mice resulted in normal glandular structures [116]. These data strongly suggest 
that different SFK members have different roles in mediating prostate cancer progression. 
Understanding these roles may be of critical importance because of the recent failure of 
an SFK inhibitor, Dasatinib in an international phase-3 clinical trial [117]. Numerous 
investigators have suggested that this failure may be due to lack of understanding of specific 
and overlapping roles of SFKs in tumor progression and bone metastasis [118-120]. Strikingly, 
there have been no studies published on specific roles of Yes in these processes; the work in 
my thesis has provided an understanding of some of its critical functions.  
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Figure 6: Structure and activation of SFKs. In an inactive status, SFKs are in a "closed" 
conformation by intramolecular interactions between SH-3 domain and Pro-X-X-Pro domain 
and between SH-2 domain and negative regulatory phosphorylated tyrosine 527 residue. This 
closed conformation limits accessibility of the kinase domain active site for substrates. SFKs 
attains a more "open" conformation through phosphatase-mediated dephosphorylation of the 
Y527 residue and higher affinity of SH-2 and SH-3 domains to activated binding partners and 
also through phosphotyrosine residues and Pro-X-X-Pro motifs. Further phosphorylation at 
tyrosine 416 in SH-1 kinase domain is required for “complete” kinase activity of SFKs, leading 
to open accessibility of substrates to the active binding sites of the kinase domain.  
From Yeatman TJ (2004) A renaissance of SRC. Nat Rev Cancer 4(6):470-480. Reproduced 
with permission. 
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Differential roles of Yes kinase in regulating cellular signaling 
Since, Src and Yes kinase are the two most structurally similar members with about 90% 
structural homology, there are signaling and functional redundancies in between these two 
kinases[121]. However, there are also specific structural and functional differences between 
Yes and Src kinase indicating a possibility of different roles in tumor progression [121, 122]. 
These structural differences suggest the possibility of different roles and indeed a previous study 
from our lab has indicated that Yes activation portends poorer survival in colorectal metastases 
than does Src activation [123]; however, these correlative studies have not defined specific roles 
for Yes. As indicated above, a potential role for Yes activation in promoting prostate cancer 
progression or metastases was unknown before the work performed in my thesis. 
Summary of problems and hypothesis 
Prostate cancer is the second leading cause of cancer-related deaths in men in the Unites 
States [1]. Although, the five-year survival rate of patients with early-stage disease is ~99%, 
the survival rate of patients with metastatic disease including to the lymph node and bones, 
drastically decreases to 31% [124]. Thus, understanding the molecular mechanisms that drive 
prostate cancer metastasis could lead to development of novel therapeutic strategies to prevent 
metastasis.  
The goal of this PhD. thesis was to focus on specific aspects of migration, an early step 
in the metastatic cascade [81]. One of the mediators of migration of cells is FAK [85]. 
Additionally, FAK is overexpressed in prostate cancer [91, 125]. However, whether FAK has a 
role in increased metastasis of prostate cancer remains unknown. FAK is phosphorylated by 
SFKs and SFK-mediated FAK phosphorylation is one of the mechanisms that regulate 
- 26 - 
 
migration of cells [94, 106]. SFKs also regulate numerous biological properties that promote 
metastasis of prostate cancer including migration of cells and increased SFK activity is 
associated with prostate cancer progression [100, 106]. However, a novel small molecule 
inhibitor of SFK has failed to show significant improvement in overall survival in patients with 
metastatic castrate resistant prostate cancer [117], indicating the need for a deeper 
understanding of the molecular mechanisms that are regulated by different SFK members. 
Current knowledge implicates, Src (a member of the SFK) as the major kinase that 
phosphorylates FAK [126]. However, recent evidence indicates that different SFK members 
have different role in prostate cancer progression [113, 116, 127]. Hence, the emphasis was to 
understand if specific changes in the FAK-SFK complexes could be identified that promote 
migration and affect important processes of metastasis. 
Recent studies have demonstrated increased phosphorylation FAK Y861 in migration 
of prostate cancer cells [78]. However, the cause and effect of this phenomenon is still unclear. 
Therefore, the first question addressed in this dissertation is whether all the tyrosine residues on 
FAK are phosphorylated equally in the PC3 Mig-3 and DU145 Mig-3 cells and specifically 
understanding the role of increased phosphorylation of FAK Y861 in highly migratory prostate 
cell models, which were developed by me. The second question was what is the association of 
increased phosphorylation of FAK Y861 in survival of patients? The third question was what 
is the mechanism of increased phosphorylation of FAK Y861, leading to understanding the 
roles of Yes kinase in preferential phosphorylation of FAK Y861? In addition, the fourth 
question was whether Yes kinase promotes prostate cancer metastasis and if increased Yes 
expression is associated with prostate cancer progression in patients. 
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The hypothesis tested in this dissertation was that changes in the FAK/SFK complexes 
dictate the increased migration in prostate cancer cells and promotes prostate cancer metastasis. 
To test this hypothesis, I first isolated highly migratory variants of prostate cancer cells named 
PC3 Mig-3 and DU145 Mig-3 from parental PC3 and DU145 cells. I then examined the role of 
pFAK Y861 in migration of these cells by overexpressing its non-phosphorylatable form FAK 
Y861F in the PC3 Mig-3 cells and then investigated the relevance of pFAK Y861 expression 
with survival of prostate cancer patients. Then, I investigated the mechanism of increased 
phosphorylation of FAK Y861 by silencing Yes in PC3 Mig-3 and overexpressing Yes kinase 
in parental PC3 cells. Finally, I assessed the role of Yes kinase in prostate cancer metastasis in 
vivo and investigated the clinical relevance of Yes expression in matched primary tumor and 
lymph node metastasis from patients. Together, this work addressed the mechanism and 
biological function of FAK Y861 phosphorylation and providing a better understanding of the 
mechanism for prostate cancer metastasis.  
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Cell culture 
 Human prostate cancer cells lines; PC3 cells were a gift from Dr. Isaiah J. Fidler’s 
laboratory and were maintained in DMEM F-12 (Hyclone) supplemented with 10% FBS 
(Hyclone). DU145 cells were a gift from Dr. Renata Pasqualini’s laboratory and were 
maintained in RPMI 1640 (Corning cell gro) supplemented with 10% FBS (Hyclone). SYF 
(Src-/-, Yes-/-, Fyn-/-) mouse embryonic fibroblasts were bought from ATCC and grown in 
DMEM media containing 10% FBS, glutamine and pyruvate. Cell cultures were incubated in 
5% CO2/95 % air tissue culture incubators at 37
oC. Cells were checked every three months to 
be mycoplasma free. Fingerprinting analysis was performed on these cell lines by the M.D 
Anderson Cancer Center Department of Systems Biology and the identities of these cell lines 
were confirmed. The analysis was performed using the AmpF_STR Identifier kit according to 
the manufacturer’s instructions (Applied Biosystems #4322288). The STR profiles were 
compared to known ATCC DNA fingerprints (ATCC.org) and to the cell line integrated 
molecular authentication database (CLIMA) version 0.1.200808 (http:// 
bioinformatics.istge.it/clima/) (Nucleic Acids Research 37:D925-D932 PMCID: 
PMC2686526). 
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Migration assay 
 Migration abilities of the PC3 and DU145 cells were determined by the modified 
Boyden chamber migration assay as described by Lesslie et al. [98]. Briefly, PC3 and DU145 
cells were trypsinized and plated (0.05 X 106) in the upper well of the 8.0µm pore size 
polyethylene terephthalate membrane culture inserts for 24 well plates (BD Biosciences, 
Medford MA) in 500µL DMEM/F12 media without FBS. The lower chamber was filled with 
750µLof DMEM/F-12 supplemented with 10% FBS as a chemo attractant. After 24 hours, the 
non-migratory cells from the upper chamber were scraped using a cotton swab. The cells that 
had migrated in the lower chamber were fixed and stained with HEMA-3 stain kit (EMD, 
Millipore) according to the manufacturer’s protocol. Migrated cells were counted in 100X 
magnification under the microscope in five random fields/inserts in triplicates. Each experiment 
was performed in triplicates. 
Time-lapse microscopy and quantification of cell migration 
Subconfluent tumor cells were detached with 2mM EDTA (Ambion #AM9260G), 
embedded (33,000/100 μl) in bovine collagen (PureCol, Advanced BioMatrix, Catlog #5005-
B; final concentration 1.7 mg/ml), and afterwards incorporated into a self-constructed chamber. 
To construct the migration chamber an object slide and a coverslip were connected by a spacer 
composed of vaseline / paraffin (1:1), resulting in an approximate chamber size of 20 x 20 x 0.5 
mm and a volume of ~200 μl. After addition of medium, spontaneous migration was monitored 
by digital time-lapse, bright-field inverse microscopy (air objectives, 10×, NA 0.20; Leica) at 
37°C using CCD cameras (Sentech) and the 16-channel frame grabber software (Vistek) for 24 
hr. with 4-min frame intervals. Migration speed was quantified by computer-assisted cell 
tracking (Autozell 1.0 software; Centre for Computing and Communication Technologies 
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[TZI], University of Bremen, Bremen, Germany) of xy paths with 12-min step intervals (tumor 
cells). The average speed per cell was calculated from the length of the path divided by time, 
including “go” and “stop” phases. 
Invasion assay 
 Invasion abilities of the PC3 and DU145 cells were determined by the modified Boyden 
chamber invasion assay as described by Lesslie et al.[98]. . Briefly, parental PC3 cells (0.5 X 
106) were suspended in the upper well of the 8.0µm pore size polyethylene terephthalate 
membrane culture inserts for 24 well plates coated with matrigel (BD Biosciences) in 500µL 
DMEM/F12 media without FBS. The lower chamber was filled with 750µLof DMEM/F-12 
with 10% FBS as a chemo-attractant. After 24 hours, the non-invasive cells from the upper 
chamber were scraped using a cotton swab. The cells that had invaded in the lower chamber 
were fixed and stained with HEMA-3 (Biochemical Sciences) according to the manufacturer’s 
protocol. Invasive cells were counted in 100X magnification under the microscope in five 
random fields/inserts in triplicates.   
Adhesion assay 
PC3 and DU145 cells (5 X 104 cells/ 100µL) were seeded into each well of a 96 well 
plate. The plates were incubated for 30 minutes in 37oC; the wells were washed with PBS three 
times and incubated with 1µmol/L Calcein AM (Invitrogen Life Technologies, Grand Island, 
NY, USA) for 3 minutes. The cells that adhered to the plate were quantified by measuring the 
fluorescence intensity at 458/528 nm in each well on a Synergy HT fluorescent plate reader 
(BioTeK). 
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Proliferation assay 
 3 x 104 cells / well were cultured in 6-well dishes for up to 96 hours. For cell counting, 
at various time points, the media was removed, cells were washed with once PBS (Gibco), and 
500µl TrypLE dissociation reagent (Gibco) was added to each well. Cells were then incubated 
for 5 minutes at 37ºC. Complete media (1ml) was then added to each well, and cells were 
resuspended with a micropipette. 500µl cell suspension was transferred into a separate cup 
(Beckman Coulter) and cells were counted using an automated cell viability analyzer Vi-Cell 
XR (Beckman Coulter). All experiments were performed in triplicate. 
Immunoblotting 
 Clarified cell lysates (50µg/lane) were separated by SDS-PAGE on 8% gels and 
electroblotted onto PVDF (Immobilin-P) membranes (EMD Millipore, Billerica, MA,USA) as 
described previously(). Membranes were blocked with 5% skimmed milk in TBS-T and 
incubated with primary antibodies (listed in table) overnight at 4oC. All mouse monoclonal 
antibodies were followed by horseradish peroxidase-conjugated rabbit anti-mouse IgG (ICN 
Biochemicals Inc., Costa Mesa, CA, USA); rabbit polyclonal antibodies were followed with 
horseradish peroxidase conjugated goat anti-rabbit IgG. Specific binding was determined using 
the Pierce ECL western blotting substrate (Thermo Fisher Scientific, Waltham, MA, USA). 
Immunoprecipitation 
Cells were rinsed with ice cold PBS, then detergent lysates were made in a standard 
Radio Immuno Precipitation Assay ‘A’ buffer (Garcia et.al 1991). Cells were homogenized and 
clarified by centrifugation at 10000g. Cell lysates (500 µg protein) were reacted for 12 hours 
with the monoclonal antibody for anti-Src (Cell Signaling Technologies, Inc., Danvers, 
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MA,USA), Yes, Fyn and Lyn (Santa Cruz Biotechnology, Dallas, TX,USA). The next day, 
50µL of 1:1 slurry of protein ‘A’ or protein ‘G’ agarose beads (Millipore) in NP-40 buffer was 
added to the protein lysate- antibody mixture and incubated for an additional 2 hours in 4oC. 
Bound proteins were pelleted by centrifugation, washed three times with Np-40 buffer, and 
eluted by boiling in 1X Lamelli’s sample buffer. Bound proteins were subjected to western blot 
analysis as described above. 
RNA isolation and quantitative RT-PCR 
RNA was isolated from the cells using RNAeasy™ mini kit (Catalog # 74104, Qiagen, 
Valencia, CA, USA) according to the manufacturer’s instructions. Briefly, total RNA (200ng) 
was reverse transcribed by using a cDNA synthesis kit (Invitrogen, Life Technologies, Grand 
Island, NY, USA) according to the manufacturer’s instructions. Gene expression was 
determined by quantitative PCR (qPCR) using KiCq Start SYBR Green kit (Sigma). The primer 
sequences for Yes were forward- TCCTGCTGGTTTAACAGGTGGTG and reverse-
TGCTTCCCACCAATCTCCTTCC 
Rho-A activation assay 
Rho-A activation was determined by Rho G-LISA™ assay kit according to the 
manufacturer’s instructions (Cytoskeleton Inc., Denver, CO, USA). Samples were prepared 
according to the instructions. Briefly, PC3, PC3 Mig-3, and Mig-3 FAKY 861-F cells were 
grown in subconfluent conditions for 3 days. The cells were then counted and plated in 12 well 
plates in serum-free media overnight. The cells were then stimulated with 10% FBS containing 
media and lysates were made from the cells immediately after 0, 6, 12, and 30 minutes. Protein 
assay was performed and an equal amount of protein was added to the wells of the Rho G-LISA 
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plate coated with Rho-GTP binding protein. The plate was placed in a cold micro plate shaker 
at 300rpm at 4oC for 30 minutes. The plate was then washed 3 times with wash buffer at room 
temperature. Then anti-Rho an antibody (1:250 dilution) was added to each well and the plate 
was placed on the shaker for an additional 30 minutes. After three washes, the horseradish 
peroxidase reagent was added to the wells. The luminescence signal from the wells was read 
@490 nm using a microplate spectrophotometer. Results are shown as absorbance over the 
background signal (background signal is incubation from the assay reagent only). 
Lentiviral-mediated pFAK Y861F expression 
The FAK Y861F, WT FAK and empty vector plasmids were constructed by Dr. Rebecca 
Schweppe’s lab (University of Colorado, USA). These plasmids contain a blasticidin resistant 
gene and a gene encoding V5 tagged mutant FAK Y861F. The lentivirus was infected (MOI: 
11) into the PC3-Mig 3 cells using 4µg/mL polybrene. After 24 hours of infection, the media 
was replaced with DMEMF12 and RPMI 1640 containing 10µg/ml Blasticidin Hcl.  
Lentivirus-mediated Yes silencing 
 Mission shRNA bacterial glycerol stock plasmids for Yes were purchased from Sigma-
Aldrich. Sequences used for Yes were 
TRCN0000001611:CCGGACCACGAAAGTAGCAATCAAACTCGAGTTTGATTGCTAC
TTTCGTGGTTTTT,TRCN0000010006:CCGGTGGTTATATCCCGAGCAATTACTCGAG
TAATTGCTCGGGATATAACCATTTTT. A non-targeting control was used along with the 
shRNA plasmid. The knockdown of Yes using both the sequences was confirmed by 
immunoblotting. For lentivirus production, the pLKO.1-puro plasmid (3 µg) was co-transfected 
with the packaging plasmid pCMV-dR8.2 dvpr (3 µg) and the envelope plasmid pCMV-VSV-
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G (0.6 µg) in a ratio of 5:5:1 into 293FT cells in one 100-mm plate (Life Technologies) using 
Lipofectamine 2000 (Life Technologies). After 24 hours incubation in culture, medium was 
replaced with 20% FBS. The viral supernatant was collected after 24 hours and again at 48 
hours, filtered through 0.45 µm filters followed by centrifugation at 20,000 rpm for 2 hours at 
4 ℃. The viral pellet was resuspended in 200 µl of RPMI medium and stored at -80 ℃. Cells 
were cultured in 48-well plates were incubated with 20 µl of virus supernatant in the present of 
8 μg/ml of polybrene (Sigma) and centrifuged at 500 ×g for 20 min and further incubated for 
24 hr. The medium was changed after 24 hours and replaced again with 5 μg/ml puromycin 
after 48 hours and incubated for one week to select stable silenced cells.  
Yes kinase overexpression  
Yes was transiently overexpressed in the PC3-P cells using the PCMV6-XL5 Yes 
overexpression plasmid. (Catalog # SC116734, OriGene Technologies, Inc., Rockville MD, 
USA). The negative control was provided by the manufacturer (Catalog # PCMV6-XL5). The 
Yes plasmid was sequenced using VP1.5 (forward) 5' GGACTTTCCAAAATGTCG 3' and 
XL39 (reverse) 5' ATTAGGACAAGGCTGGTGGG 3' 
Src kinase overexpression  
Full-length c-Src was cloned in PCDNA3.1 plasmid as described by Trevinio JG et. al. 
[128] . 2µg of the plasmid was used to transfect the SYF cells and the PC3 cells using the 
jetPRIME (Polyplus-transfection, Illkirch, France) according to the manufacturer’s instructions. 
The cells were selected with 100 µg/mL of G418 antibiotic containing DMEMF-12 media 
containing 10% FBS. The PC3-Src cells were selected and cultured to get a stable cell line 
overexpressing Src. 
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Immunohistochemical staining  
 Immunohistochemistry was performed as described previously. Briefly, paraffin 
embedded tissue sections were heated at 65oC overnight before deparaffinization in xylene, 
followed by treatment with graded series of alcohols (100%,95%,80% ethanol [vol/vol] in 
double distilled H2O) and rehydration with PBS (pH 7.5). For antigen retrieval, tissues were 
submerged in 0.1 M EDTA and Citrate buffer for pFAK Y861 and pFAK Y397 respectively in 
a pressure cooker for a total of 40 minutes (4 minutes actual cook time). After washing with 
PBS endogenous peroxidases were blocked with 3% hydroxyl peroxide (H2O2) in PBS for 12 
minutes, followed by three washes in PBS. The sections were blocked with cyto Q background 
buster for 30 minutes followed by incubation with the primary antibodies in Immunodiluent 
(Innovex) overnight at 4oC. After washing with PBS, the slides were incubated with HRP Mach-
4 polymer anti-rabbit antibody (Bio care, Concord, CA, USA) for 1 hour. After 3 washes with 
PBS the chromogenic reaction was visualized using 3-3’ diaminobenzidine (DAB) solution 
(Invitrogen, Life Technologies, Grand Island, NY, USA) for 3 minutes or until good color 
formation was observed by monitoring the reaction under the microscope. The sections were 
counter stained with Gill’s hematoxylin solution for 1 minute, and mounted with universal 
mount (Research Genetics, Inc. AL,USA). 
Quantification of immunohistochemical staining 
Quantification of immunohistochemical staining for expression of Yes and pFAK Y861 
was performed using the NIH ImageJ software. The tumor tissue was scanned under bright field 
(magnification 100X, 0.14 mm2) using Sony DXC-990 three chip charged-coupled device color 
video camera mounted on Nikon-Microphot-FX microscope (Nikon Co.). Five representative 
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images were selected randomly analyzed. Images were then processed and quantified using 
Image J, a public domain Java image-processing program (U. S. National Institutes of Health, 
Bethesda, Maryland, USA). Briefly, brown-colored images specific for DAB stain were 
extracted by the color deconvolution macro, inversed and measured for intensity using NIH 
ImageJ internal commands. All intensity values in the group were averaged to calculate 
intensity of pFAK Y861 and Yes expression in primary tumors and lymph node metastasis 
tissue as described by Park SI et al. [114]. 
In vivo tumorigenicity assay  
PC3-P and PC3 Mig-3 cells were detached from subconfluent cultures and a desired 
number of cells were centrifuged and resuspended in Ca2+-free and Mg2+-free HBSS (Life 
Technologies, Austin, TX, USA). For implantation of the cells in prostate, the procedure of Kim 
et al. was followed. Male athymic nude mice (Ncr nu/nu; ages 8-12 weeks; the National Cancer 
Institute-Fredrick Animal Production Area) were anesthetized with pentobarbital sodium i.p 
(0.5mg/1gm of body weight; Nembutal (Abbott laboratories, Abbott Park, IL, USA) and placed 
in a supine position. A midline incision was made in the lower abdomen and the prostate was 
exteriorized. 50µL of HBSS containing 125,000 PC3-P cells and (125,000, 500,000 and 1X106) 
Mig-3 PC3 cells were injected to the dorsolateral side of the prostate. The incision was closed 
with surgical metal clips (Braintree Scientific, Inc., Braintree, MA, USA). 
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Statistics: 
Statistical analyses for differences of tumor weight were performed using the GraphPad 
Prism software. ANOVA and Tukey’s test was conducted to compare differences in tumor 
weight. Incidences of tumors and lymph node metastases were compared between groups with 
the Fisher’s exact test. Migratory cell numbers in modified Boyden chamber migration assay 
were compared by Student’s t-test. Statistical analysis for pFAK Y861 and Yes 
immunohistochemistry was performed using one-way ANOVA and unpaired t-test. P values of 
less than 0.05 were considered statistically significant. 
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Chapter-3 
Biological characterization of PC3 
Mig-3 and DU145 Mig-3 cells 
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Isolation of PC3 Mig-3 and DU145 Mig-3 subclones from parental cells 
 50,000 PC3 and DU145 cells (PC3-P and DU145-P) were seeded on the upper chamber 
of the Boyden chamber for 24 hours. The cells that migrate through the chamber for 24 hours 
were collected from the bottom chamber and grown in culture. This process was repeated for 3 
cycles to isolate the more migratory from both PC3 Mig-3 and DU145 Mig-3 cells. The 
selection was continued again for one more time to get PC3 Mig-4 cells; however, there was no 
further increase in migration in the PC3 Mig-4 cells. Hence, the PC3 Mig-3 and DU145 Mig-3 
population from both the cell lines was used for further investigation. The PC3 Mig-3 and 
DU145 Mig-3 cells were grown in culture for < 30 passages and the migration abilities for the 
cells were found to be consistent.  
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Figure 7: Schema for isolation of PC3 Mig-3 and DU145 Mig-3 cells. Modified Boyden 
chamber migration assay was used to isolate highly migratory prostate cancer cells. The cycle 
of isolation was repeated three times to get a subclone of highly migratory cells. The PC3 Mig-
3 and DU145 Mig-3 cells were stable for more than 30 passages after multiple free-thaw cycles. 
 
 
 
 
 
- 42 - 
 
Morphology 
To examine the morphology of the PC3-P, PC3 Mig-3, DU145-P and DU145 Mig-3 
cells, equal number of cells were plated in culture overnight and bright field microscopy was 
performed to document morphological differences between the cell lines. Bright field 
microscopy at 10X magnification indicated no significant changes in morphology in the PC3 
Mig-3 cells relative to the PC3-P cells. Similarly, there were no significant morphological 
differences observed in the DU145 Mig-3 cells relative to the DU145-P cells. However, 
consistent to the literature we observed that DU145 cells were more mesenchymal and PC3 
cells were more epithelial (Figure 8). 
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Figure 8: Morphology of PC3 and DU145 cells. Morphology of PC3 Mig-3 and DU145 Mig-
3 cells were compared to PC3-P and DU145-P cells after examination under a light microscope. 
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Migration 
To examine whether PC3 Mig-3 and DU145 Mig-3 have increased migration relative to 
the parental cells, I performed an in vitro Boyden chamber migration assay for 24 hours. As 
shown Figure 7, PC3 Mig-3 had 94% (p<0.0001) increase in migration of PC3-P cells. 
Consistently, DU145 Mig-3 cells had an 83% (p<0.0001) increase migration field in DU145-P 
cells (Figure 9). The increase in migration of the PC3 Mig-3 and DU145 Mig-3 cells were stable 
for more than 30 passages with repeated freeze-thaw cycles. To test the increased migratory 
abilities of the PC3 Mig-3 using a second assay, we used time-lapse microscopy to determine 
the speed of migration after plating them on the cell culture plate.  
Time-lapse microscopy was performed on the PC3 Mig-3 cells and the data was 
quantified using the Auto Zell software. The speed of migration was calculated by dividing the 
distance travelled by a cell from point “A” to “B” divided by the time required to do so. On 
comparing the speed of migration within the two groups, PC3 Mig-3 had an increased migration 
speed of 0.170µm/min relative to 0.078µm/min in PC3-P cells (2-fold increase) 24 hours after 
plating the cells al PC3 cells consistent with the Boyden chamber assay data (Figure 10). To 
further characterize the molecular changes associated with migration in PC3 Mig-3 cells, we 
performed a DNA microarray using the Illumina platform. On performing an Ingenuity pathway 
analysis using the data, I observed that migration and motility pathways were the most 
differentially altered pathways at the mRNA levels (Figure 52). These data confirmed that PC3 
Mig-3 and DU145 Mig-3 cells had increased in vitro migration relative to the parental cells. 
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Figure 9: Migration assay of PC3 Mig-3 and DU145 Mig-3 cells. Migration assay was 
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The 
cells were counted at 20X magnification. Graph illustrates number of cells that have migrated. 
Bars represent the average number of cells migrated from triplicate wells. *p<0.002, ** 
p<0.0002, ***p<0.0001 by Student’s t-test, compared to the control group. Representative 
images are used to show the number of cells migrating per field. 
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Figure 10:Time-lapse microscopy to determine speed of migration. PC3-P and PC3 Mig-3 
cells were plated in bovine albumin containing chamber as described in the materials and 
methods. Spontaneous migration was recorded using time-lapse microscopy at 10X 
magnification and the speed of migration was calculated using the Auto Zell software. 
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Invasion 
Invasion of cell through the extracellular matrix is crucial for metastasis to occur. Since, 
PC3 Mig-3 and DU145 Mig-3 cells had increased migration in vitro, I further investigated 
whether, the in vitro selection for migration, selects for cells with increased invasive properties. 
To test this hypothesis, I performed an in vitro invasion assay using a modified Boyden 
chamber, coated with matrigel. As shown in Figure 10, PC3 Mig-3 cells had 95% (p<0.0001) 
increase in invasion relative to PC3-P cells. Consistently, DU145 Mig-3 cells had a 70% 
(p<0.0001) increase in invasion compared to DU145-P cells (Figure 11) correlating with the 
increased migration in both cell models.  
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Figure 11: Invasion assay of PC3 Mig-3 and DU145 Mig-3 cells. Invasion assay was 
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The 
cells were counted at 10X magnification. Graph illustrates number of cells that have migrated. 
Bars represent the average number of cells migrated from triplicate wells. *p<0.002, ** 
p<0.0002, ***p<0.0001 by Student’s t-test, compared to the control group. Representative 
images are used to show the number of cells invading per field. 
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Proliferation 
To determine whether increased migration and invasion were due to differences in 
proliferation; I examined the proliferation rates of PC3 Mig-3 and DU145 Mig-3 cells relative 
to the parental cells. Viable cells were enumerated as described in materials and methods. As 
shown in Figure 12, the doubling time for PC3-P cells was 19 hours relative to 22 hours for 
PC3 Mig-3 cells. The doubling time for DU145-P cells was 19 hours and for DU145 Mig-3 
cells, 24 hours. These data are consistent with more migratory cells having reduced proliferation 
rates [129]. 
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Figure 12: Proliferation of PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P, and DU145 
Mig-3 cells were plated 5X104 and cultured for indicated times. The cells were then stained 
with tryphan blue and counted. *p<0.005 by Student’s t-test, compared to the control group. 
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Adhesion  
Another property of a more metastatic cell is its ability to detach from the primary tumor 
site and enter the circulation. Adhesion was determined by plating 5 X104 cells in each well of 
a 96-well plate and washing with PBS after 30 minutes. The number of viable cells bound to 
the cell culture plate was determined using Calcein AM staining as described in the materials 
and methods. As shown in Figure 13, our results demonstrate that PC3 Mig-3 cells had a 33% 
decrease in adhesion relative to PC3-P cells (p<0.005). Likewise, DU145 Mig-3 cells had a 
63% decrease in adhesion relative to DU145-P cells (p<0.003). These results indicate that PC3 
Mig-3 and DU145 Mig-3 have decreased adhesion relative to the parental cells. 
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Figure 13: Adhesion assay of PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P, DU145 
Mig-3 cells were plated 50 X 104 for 30 minutes and washed with PBS. The cells were stained 
with Calcein AM and fluorescence intensity was measured indicating the viable cells remaining 
on the plate. The graph represents average fluorescence intensity of triplicates. *p<0.005 by 
Student’s t-test, compared to the control group. 
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PC3 Mig-3 cells are more metastatic to the lymph node relative to the parental cells in the 
prostate cancer spontaneous metastasis model  
Because of the differences in growth rate, we first examined tumor growth in vivo. We 
performed an in vivo tumorigenicity assay using the orthotopic nude mouse model. 500,000 
PC3-P and 500,000 PC3 Mig-3 cells were orthotopically implanted in the prostate of nude mice 
as described in the methods. The tumors were allowed to grow for 4 weeks and the mice were 
sacrificed to evaluate the incidence of lymph node metastasis and size of the primary tumor. As 
shown in Figure 14, PC3 Mig-3 cells were found to form significantly smaller primary tumors 
relative to parental PC3 cells (p<0.0006); however the number of lymph node metastases was 
similar. The slow in vivo growth rate of the PC3 Mig-3 was consistent with the in vitro results 
and further confirmed with Ki67 staining, which is a marker for cellular proliferation. PC3 Mig-
3 tumors had significantly less Ki67 positive cells relative to the parental primary tumors, 
represented in Figure 15. 
 To perform metastasis assays, it was desirable to measure metastasis when primary 
tumors were of similar size. Therefore a titration experiment was performed. To accurately 
examine in vivo tumorigenicity, an increasing number of PC3 Mig-3 and PC3-P cells were 
intraprostatically implanted in the nude mice, which were then sacrificed after 4 weeks to 
evaluate the size of the primary tumors and incidence of lymph node metastases. All mice 
developed primary tumors; however due to differences in proliferation rates, similar sized 
primary tumors were obtained implanting 125,000 PC3-P cells and 500,000 PC3 Mig-3 cells 
(Table 1). Lymph node metastases were assessed by identifying solid, opaque and enlarged iliac 
lymph nodes as represented in Figure 18.  
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As shown in Figure 16, similar sized primary tumors were obtained from 125,000 PC3-
P cells and 500,000 PC3 Mig-3 cells. Additionally, the PC3 Mig-3 tumors formed 4.1±0.3 
lymph node metastases relative to 1.5±0.29 lymph node metastases in PC3-P (p<0.005) tumors 
as shown in Figure 17. These data, collectively, indicate that PC3 Mig-3 cells are significantly 
more metastatic to the lymph node relative to PC3-P cells. 
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Figure 14: In vivo growth of PC3-P and PC3 Mig-3 cells. 500,000 PC3-P and 500,000 PC3 
Mig-3 cells were injected intraprostatically. The tumors were grown for 4 weeks and the tumor 
weight was determined after sacrificing the mice. *p<0.005 by ANOVA and Tukey’s test, 
compared to the control group.  
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Table 1: Average tumor weight and incidence of lymph node metastasis 
*ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, *p<0.005 
 
 
 
 
 
 
 
- 57 - 
 
 
 
 
Figure 15:Ki67 staining on PC3-P and PC3 Mig-3 tumors. Ki67 staining in fixed sections 
from the primary tumors from the PC3-P and PC3 Mig-3 cells. *p<0.005 by Student’s t-test, 
compared to the control group. 
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Figure 16: Tumor weight of PC3-P and PC3 Mig-3 cells. Variable amounts of PC3 Mig-3 
cells (125000, 250000 and 500000) and 125,000 PC3-P cells were injected intraprostatically in 
the nude mice. The tumors were grown for 4 weeks and the tumor weight was determined after 
sacrificing the mice. *p<0.05, ** p<0.005 by ANOVA and Tukey’s test, compared to the 
control group. 
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Figure 17: Incidence of lymph node metastasis of PC3-P and PC3 Mig-3 cells. Variable 
amounts of PC3 Mig-3 cells (125000, 250000 and 500000) and 125,000 PC3-P cells were 
injected intraprostatically in the nude mice. The tumors were grown for 4 weeks and the 
incidence of metastasis was determined after sacrificing the mice. ** p<0.005 by ANOVA and 
Tukey’s test, compared to the control group. 
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Table 2: Average weight of primary tumor and lymph node metastases following 
different numbers of PC3 Mig-3 cells injected intraprostatically 
ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, *p<0.005, **p<0.001 
 
 
 
 
 
Group Average Tumor 
wt. (mg)/ range 
Incidence 
of 
primary 
tumor 
Average 
incidence of LN 
mets/ range 
Incidence of LN 
Metastases 
PC3-P (125,000) 598.5 (220-875)* 9/9 1.8 (1-3)** 9/9 
PC3 Mig-3 (125,000) 183.1 (45-349) 7/7 2.7(2-4) 7/7 
PC3 Mig-3 (250,000) 339.5 (204-490) 7/7 2.6(1-3) 7/7 
PC3 Mig-3 (500,000) 423.5 (303-730)* 7/7 4.1( 3-5)** 7/7 
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Figure 18: Tumor weight and incidence of lymph node metastasis of PC3-P and PC3 Mig-
3 cells. Representative images of the primary tumors and lymph node metastasis isolated from 
after intraprostatic injections. 
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Chapter-4 
Molecular characterization of FAK in 
PC3 Mig-3 and DU145 Mig-3 cells 
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Increased expression of pFAK Y861 is associated with increased migration in PC3 Mig-3 
cells 
To examine the role of FAK in increased migration of PC3 Mig-3 and DU145 Mig-3 
cells, levels of FAK expression and phosphorylation were determined by immunoblotting as 
described in material and methods. As shown in Figure 19 and 20, total levels of FAK 
expression in PC3 Mig-3 and DU145 Mig-3 cells were similar. However, in both the PC3 Mig-
3 and DU145 Mig-3 cells, there was no increase in FAK Y397 phosphorylation (the 
autophosphoryation site) and there was no increase in phosphorylation of the SFK-dependent 
phosphorylation sites FAK Y401, FAK Y577, FAK Y576 and FAK Y925). In contrast, in both 
PC3 Mig-3 and in DU145 Mig-3, an increase in pFAK Y861 expression was observed relative 
to the cognate parental cell lines.  
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Phosphorylation of FAK Y861 is critical to migration 
To determine if pFAK Y861 increases were likely the most important alterations to 
migratory potential, I examined two additional proteins known to promote prostate cancer cell 
migration and overexpressed during tumor progression, Met and Axl [130, 131]. Roles of Axl 
and Met were potentially important as in my uncloned population of Mig-3 cells (both PC3 and 
DU145), were increased in expression of these proteins (as well as Yes, discussed below). To 
examine if Axl and/or Met to contributed to migration, single cell cloning of PC3 Mig-3 was 
performed and individual cell lines were isolated. Expression of key proteins under 
investigation from five clones is shown in (Figure 21). Each clone consistently overexpressed 
Yes and FAK pY861. However, Met and Axl were variably expressed with some clones 
overexpressing both proteins, some failing to overexpress either protein, and other clones 
overexpressing either Met or Axl but not both. To determine the potential contribution of Met 
and Axl to subclones of PC3 Mig-3 cells, representative examples were chosen in which Met 
and/or Axl were overexpressed (see Figure 21 with differential expression of these proteins), 
and migration assays were performed as previously described. As shown in Figure 21, neither 
increased expression of Met, nor Axl nor both led to increase in vitro migration of PC3 Mig-3 
clones relative to parental cells. Importantly, the only consistent alteration that correlated with 
increased migration in all of the clones of PC3 Mig-3 cells was increased levels of pFAK Y861 
(Figure 22). The significance of Yes kinase in PC3 Mig-3 cells will be discussed in the next 
chapter. These results indicated that increased expression of pFAK Y861 is independent of Axl 
or Met expression and is most associated with increased of PC3 Mig-3 cells by the selection 
procedure used.  
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Figure 19: Phosphorylation of FAK in PC3 cells after migration selection. PC3-P, PC3 
Mig-1, PC3 Mig-2, PC3 Mig-3 cells were grown in culture. The cells were lysed and subjected 
to immunoblot analysis to determine expression of pFAK Y861, pFAK Y397, pFAK Y577, 
pFAK Y401, pFAK Y576, pFAK Y925 and total FAK expression. Relative expression was 
determined after normalization against total FAK expression using NIH ImageJ. 
 
- 66 - 
 
 
R
e
la
t
iv
e
 e
x
p
r
e
s
s
io
n
p
F
A
K
 Y
8
6
1
p
F
A
K
 Y
4
0
1
p
F
A
K
 Y
5
7
6
p
F
A
K
 Y
5
7
7
p
F
A
K
 Y
9
2
5
p
F
A
K
 Y
3
9
7
0
1
2
3
4
D U 1 4 5 - P
D U 1 4 5  M ig - 1
D U 1 4 5  M ig - 2
D U 1 4 5  M ig - 3
              
Figure 20: Phosphorylation of FAK in DU145 cells after migration selection. DU145-P, 
DU145 Mig-1, DU145 Mig-2 and DU145 Mig-3 cells were grown in culture. The cells were 
lysed and subjected to immunoblot analysis to determine expression of pFAK Y861, pFAK 
Y397, pFAK Y577, pFAK Y401, pFAK Y576, pFAK Y925 and total FAK expression. Relative 
expression was determined after normalization against total FAK expression using NIH 
ImageJ. 
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Figure 21: Expression of proteins involved in migration after subcloning in PC3 Mig-3 
cells. PC3 Mig-3 cells were subjected to single cell cloning and subpopulations of PC3 Mig-3 
cells were grown in culture. The clones were lysed and the protein was subjected to immunoblot 
analysis for expression of Met, Axl, Yes and pFAK Y861. 
* indicate the clones used for migration assay 
       
* * * 
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Figure 22: Migration of the clones of PC3 Mig-3 cells. Specific subclones of PC3 Mig-3 
cells, which had differential expression of Axl, and Met, were tested for migration abilities 
using a modified Boyden chamber. The cells were allowed to migrate for 24 hrs. The cells after 
fixation and staining were stained counted under 20X magnification Significance of differences 
within the cell lines were calculated and statistics represent migration relative to PC3 Mig-3 
cells. **p<0.0005 by Student’s t-test, compared to the control group. 
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Phosphorylation of FAK Y861 is associated with increased migration of PC3 Mig-3 cells 
To determine if pFAK Y861 is required for migration of PC3 Mig-3 cells, I 
overexpressed a non-phosphorylatable form of FAK (FAK Y861F) (Figure 23) as described in 
the materials and methods. As shown in Figure 24, no effect on proliferation of PC3 Mig-3 
FAK Y861F cells was observed. As shown in Figure 25, in vitro migration of PC3 Mig-3 FAK 
Y861F cells was reduced by 90% compared to the empty vector control in a 24 hour Boyden 
chamber migration assay (p<0.0001), consistent with results from other cell lines demonstrating 
the importance of FAK Y861 phosphorylation in migration [78] [93]. These data confirm that 
phosphorylation of FAK Y861 regulates migration of PC3 Mig-3 cells.  
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Figure 23: Overexpression of FAK Y861F plasmid in the PC3 Mig-3 cells A. Map of the 
plenti6/V-5D-TOPO vector used for expression of pFAK Y861F mutant. B. Immunoblot 
analysis of FAK Y861F cells to determine the expression of V5-FAK. 
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Figure 24: Effects of FAK Y861F expression on cell growth of PC3 Mig-3 cells. PC3 Mig-
3, PC3 Mig-3 Vector control and FAK Y861F Mig-3 cell lines were equally plated in culture. 
The cells were trypsinized and counted after tryphan blue staining for 6 days. The cell numbers 
were plotted and the growth rate was determined. 
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Figure 25: Effect of FAK Y861F expression in PC3 Mig-3 cells. Migration assay was 
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The 
cells were counted at 20X magnification. Graph illustrates number of cells that have migrated. 
Bars represent the average number of cells migrated from triplicate wells. ** p<0.0005, 
***p<0.0001 by Student’s t-test, compared to the control group. Representative images are 
used to show the number of cells migrating per field. 
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Rho-A activation is associated with increased migration of PC3 Mig-3 cells 
Rho-A is activated downstream of FAK phosphorylation to induce migration of PC3 cells [132]. 
To investigate the activation of Rho-A in the PC3 Mig-3 cells, G-LISA Rho-A activation assay 
was used. On stimulation of the cells with 10%, FBS had significantly PC3 Mig-3 cells had 
significantly higher Rho-A activation relative to PC3-P cells. Additionally the PC3 Mig-3 FAK 
Y861F cells were used as a negative control, since they were found to be low migratory in vitro. 
As shown in Figure 26, PC3 Mig-3 FAK Y861F cells had significantly less Rho-A activation 
relative to the PC3 Mig-3 cells. These data confirmed activation of Rho-A is one of the 
downstream pathways that is associated with increased migration in PC3 Mig-3 cells, consistent 
with many studies demonstrating the role of Rho-A in mediating FAK migration. 
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Figure 26: Rho-A activation status in PC3 Mig-3 cells. PC3-P, PC3 Mig-3 and FAKY861F 
Mig-3 cells were equally plated in culture overnight. Rho-A activation was determined using 
the G-LISA Rho-A activation assay kit after serum stimulation for 6 mins, 12 mins and 30 
mins. Error bars represent average Rho-A activity from triplicate wells.*p<0.005, **p<0.001 
by Student’s t-test, compared to the control group. 
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Spontaneous metastases of PC3 Mig-3 cells to the lymph nodes are increased in expression 
of pFAK Y861  
As discussed before, PC3 parental cells are able to metastasize to the lymph node following 
orthotopic injection. I therefore determined if the lymph node metastases from PC3-P were also 
increased in pFAK Y861. Which would suggest that increased pFAK Y861 is a general property 
of lymph node metastasis development. In PC3 Mig-3 cells and PC3-P cells, pFAK Y861 
expression in the primary tumors was estimated by immunohistochemistry. As shown in Figure 
27, a 2.5-fold increase was observed in expression of pFAK Y861 in the PC3 Mig-3 primary 
tumors relative to the PC3-P primary tumors. As PC3-P tumors also form lymph node 
metastases, we next examined if these lymph node metastases were selected for increased pFAK 
Y861 expression. Immunohistochemistry for pFAK Y861 was performed on tumor-positive 
lymph nodes harvested from the metastasis experiment described above. Lymph node 
metastasis in PC3-P tumors had a 2.3-fold increase in pFAK Y861 expression relative to the 
PC3-P primary tumors. These results demonstrate that lymph node metastases are increased in 
expression of pFAK Y861. As expected, in PC3 Mig-3 cells in which pFAK Y861 was already 
increased, both primary tumors and lymph node metastases showed high levels of pFAK Y861. 
Similar to what was observed in PC3 Mig-3 tumors, pFAK Y861 was also increased in lymph 
node metastases, suggesting that overexpression of pFAK Y861 may promote lymph node 
metastasis. 
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Figure 27: pFAK Y861 expression in mice prostate cancer samples.  
A. Immunohistochemical staining for pFAK Y861 expression in primary tumor and lymph 
node metastases after orthotopic implantation of PC3-P and PC3 Mig-3 cells in prostate of the 
nude mice. B. The staining was quantified after DAB extraction using NIH ImageJ. *p<0.008, 
**p<0.001 by Student’s t-test, compared to the control group. PT=parental tumor; LN=lymph 
node metastases 
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Chapter-5 
Elucidating the mechanism of 
increased migration in PC3 Mig-3 and 
DU145 Mig-3 cells 
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Candidate approach to identify proteins associated with increased phosphorylation of FAK 
Y861 
Phosphorylation of FAK Y861 is one of the signature alterations associated with the 
PC3 Mig-3 and DU145 Mig-3 cells. My next goal was to determine whether this increased 
phosphorylation was due to increased kinase expression, or decreased phosphatase expression. 
The cDNA microarray data performed in collaboration with Woonyoung, Ph.D. and David 
McConkey, Ph.D. demonstrated downregulation of Src homology-domain containing tyrosine 
phosphatase (Shp-2) in PC3 Mig-3 cells relative to the PC3-P cells. However, immunoblot 
analysis indicated that Shp-2 levels were not altered after translation at the protein levels, as 
shown in Figure 28 A. These data suggested that Shp-2 was unlikely to be responsible for altered 
FAK Y861 phosphorylation in the PC3 Mig-3 phenotype. We next investigated a kinase (PTK6) 
reported to associate with pFAK Y861 [128]. As shown in Figure 28 B, immunoblot analysis 
indicated that PTK6 was not altered in expression PC3 Mig-3 cells relative to PC3-P cells. 
Collectively, these data indicated no alterations in expression levels of Shp-2 and PTK6 are 
associated with the PC3 Mig-3 cells. 
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Figure 28: Shp-2 and PTK6 expression in PC3 and DU145 cells. 
A. Immunoblotting of Shp-2. PC3-P and PC3 Mig-3 were grown in culture. The cells were 
lysed and subjected to immunoblot analysis B. Immunoblotting of PTK6. PC3-P and PC3 
Mig-3 cells were grown in culture, lysed and 15µg of total protein lysate was subjected to 
immunoblot analysis. 
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Yes kinase overexpression and increased activity correlates with increased migration in PC3 
Mig-3 cells 
Src family kinases (SFK’s) phosphorylate all of the FAK tyrosine phosphorylation sites 
excluding the autophosphorylation site (FAK Y397) [126]. Hence, I investigated the expression 
and activity of SFK’s in PC3 Mig-3 and DU145 Mig-3 cells relative to parental cells. 
Expression of SFKs was examined by immunoblot analysis. As shown in Figure 29, no 
increased expression of Src, Fyn and Lyn were observed. However, a 2.5-fold increase in Yes 
expression was observed in PC3 Mig-3 cells relative to PC3-P cells. Similarly, the DU145 Mig-
3 cells had a 2-fold increase in Yes expression relative to DU145-P cells, but no increase in 
other Src family members expressed in these cells as shown in Figure 30. As determined by rt-
qPCR, c-yes mRNA was also increased 1.5-fold in the PC3 Mig-3 and DU145 Mig-3 cells 
relative to the PC3-P and DU145-P cells, as shown in Figure 31. As FAK is phosphorylated by 
SFKs, we next examined kinase activity of Src family members. As antibodies specific to the 
autophosphorylation sites (indicative of active forms of these enzymes) to specific SFKs have 
not been generated), to examine kinase activity of SFKs expressed in these cells, 
immunoprecipitation of individual SFKs  was performed using specific antibodies to each and 
then blotted with antibody against the autophosphorylation site. This was necessary because the 
antibody to the autophosphorylation site recognizes this site in all the SFKs studied. As shown 
in Figure 32, no increase in expression or autophosphorylation (indicative of an activated form 
of the kinase) was observed for of Src, Lyn and Fyn (Figure 32 B, C, D) in PC3 Mig-3 cells 
relative to the PC3-P cells. However, Yes activity was increased by 3-fold in the more migratory 
PC3 Mig-3 cells relative to the parental cells (Figure 32 A).  
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Figure 29: SFK expression in PC3 cells. A. Immunoblotting of SFK expression PC3-P, PC3 
Mig-1, PC3 Mig-2 and PC3 Mig-3 cells were grown in culture and lysed. Total protein was 
subjected to immunoblot analysis. B. Quantification of the immunoblot analysis using NIH 
ImageJ normalized to the loading control. 
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Figure 30: SFK expression in DU145 cells. A. Immunoblotting of SFK expression. DU145-
P, DU145 Mig-1, DU145 Mig-2 and DU145 Mig-3 cells were grown in culture and lysed. Total 
protein was subjected to immunoblot analysis. B. Quantification of the immunoblot analysis 
using NIH ImageJ normalized to the loading control. 
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Figure 31: Yes mRNA expression in PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P 
and DU145 Mig-3 cells were grown in culture. Total RNA from the cells was extracted and 
subjected to RT-qPCR using primers specific to Yes kinase. The expression levels are 
presented relative to actin control levels **p=0.006, *p=0.002 by Student’s t-test, compared to 
the control group. 
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A.                                                                             B. 
 
 
 
 
C.                                                                                          D.                                  
 
 
 
 
Figure 32: Immunoprecipitation to determine SFK activity. PC3-P and PC3 Mig-3 cells 
were grown in culture and lysed. Yes, Src, Lyn and Fyn was immunopreciptated from equal 
amounts of protein using specific antibodies for each kinase. Immunoblotting analysis was 
performed on the immunoprecipitated lysates to determine the levels of phospho SFK. 
IP: Yes 
IB: Phospho-SFK 
IP: Src 
IB: Phospho-SFK 
IP: Lyn 
IB: Phospho-SFK 
IP: Fyn 
IB: Phospho-SFK 
- 85 - 
 
Yes kinase preferentially phosphorylates FAK Y861 in PC3 Mig-3 cells 
Next, I investigated the role of Yes kinase in FAK Y861 phosphorylation. As shown in 
Figure 33, overexpression of Yes in parental PC3 cells with an expression vector as described 
in materials and methods did not increase phosphorylation of FAK Y397, FAK Y401, FAK 
Y577 and FAK Y576. However, FAK Y861 phosphorylation was increased by 2.6-fold. In 
contrast, overexpression of Src led to an equivalent increase in phosphorylation of all SFK sites, 
as shown in Figure 36. 
 In a second approach to determine if Yes preferentially phosphorylated FAK Y861, Yes 
was silenced by in PC3 Mig-3 cells using two Yes specific shRNA sequences. Knockdown of 
Yes kinase led to decreased expression of pFAK Y861 and in pFAK Y925 with no significant 
effect on expression of the other FAK tyrosine residues, as shown in Figure 34. In contrast, 
silencing Src led to decreased phosphorylation of all the SFK phosphorylated FAK tyrosine 
residues, represented in Figure 35. To examine the role of Yes in migration, we performed a 
migration assay PC3-P cells in which Yes was overexpressed and in PC3 Mig-3 cells in which 
Yes was silenced. I found that overexpression of Yes in PC3-P cells led to a 68% (p<0.0001) 
increase in migration in PC3-P cells  (Figure 37), while knockdown of Yes in PC3 Mig-3 cells 
led to a 50% (p<0.0001) reduction in migration in PC3 Mig-3 cells (Figure 38). Collectively, 
these data indicate that migration in PC3 Mig-3 cells. These increases and decreases in 
migration correlate with the ability of Yes to phosphorylate FAK Y861, and to a lesser extent, 
FAK Y925.   
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Figure 33: Overexpression of Yes kinase in PC3-P cells A. PC3-P cells were transfected 
using the PCMV6-XL5 control and Yes plasmid for 48 hours. The cells were lysed and 15µg 
of protein was subjected to immunoblot analysis for Yes and phospho FAK expression. B. The 
relative protein expression was determined after normalization against vinculin loading control 
using NIH ImageJ. 
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Figure 34: Overexpression of Src kinase in PC3 Mig-3 cells. PC3 Mig-3 cells were 
transfected with PCDNA3.1 Src expression vector and Non-targeting control plasmids for 24 
hours and the cells were trypsinized after 48 hours of transfection. Cell lysates were subjected 
to immunoblot analyses for expression of Src and pFAK. Relative protein expression was 
determined after normalization to vinculin using NIH ImageJ. 
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Figure 35: Knockdown of Yes in PC3 Mig-3 cells. PC3 Mig-3 cells were transfected with 
PLKO. puro shYes#1006 and shYes #1611plasmids for 48 hours. The cells were lysed and 
subjected to immunoblot analysis for Yes and pFAK expression. Relative protein expression 
was determined after normalization again vinculin loading control using NIH ImageJ.  
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Figure 36: Knockdown of Src kinase in PC3 Mig-3 cells. PC3 Mig-3 cells were transfected 
with shSrc and Non-targeting control plasmids for 24 hrs. Cells were trypsinized after 48 hours 
of transfection. Cell lysates were subjected to immunoblot analyses for expression of Src and 
pFAK. Relative protein expression was determined after normalization to vinculin using NIH 
ImageJ. 
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Figure 37: Migration assay of PC3-P cells after overexpression of Yes. PC3-P cells were 
transfected with PCMV6-XL5 control and Yes plasmids for 24 hours and the cells were plated 
in the Boyden chamber for 24 hours. After 24 hours, the cells were stained and counted to 
determine the number of migrating cells. Bars represent the average number of cells migrated 
from triplicate wells. ***p<0.0001 by Student’s t-test, compared to the control group. 
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Figure 38: Migration assay of PC3-P cells after knockdown of Yes. PC3 Mig-3cells were 
transfected with shYes#1006, shYes#1611 and Non-targeting control plasmids for 24 hours 
and the cells were plated in the Boyden chamber for 24 hours for migration. After 24 hours, 
the cells were stained and counted to determine the number of migrating cells. Bars represent 
the average number of cells migrated from triplicate wells. ***p<0.0001 by Student’s t-test, 
compared to the control group. 
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Src kinase and Yes kinase regulate FAK phosphorylation differently in SYF null mouse 
embryonic fibroblasts 
While the above experiments provided strong evidence that Yes kinase preferentially 
phosphorylates FAK Y861 relative to the other FAK tyrosine sites, these experiments could not 
preclude potential roles of other SFKs expressed in prostate cancer cells. Therefore, to further 
determine whether Yes and Src differentially phosphorylated FAK, both were transiently 
overexpressed in the SYF (src-/-,yes-/-fyn-/-) mouse embryo fibroblasts using expression 
plasmids specific for Src and Yes as described in the methods. Overexpression of Src and Yes 
is shown in Figure 39. Overexpression of Src in the SYF cells led to increased phosphorylation 
of all the SFK-dependent tyrosine phosphorylation sites (Y 861, Y 407, Y 576, Y 577 and Y 
925). However, overexpression of Yes kinase led to a 2-fold increase in phosphorylation of 
FAK Y861 with a lesser (1.4-fold) increase in phosphorylation of FAK Y 925 (Figure 39); other 
sites were not appreciably phosphorylated. These data are consistent with a novel role of Yes 
kinase in preferentially phosphorylating FAK Y861 and FAK Y925, the principal tyrosine sites 
mediating migration of cells. 
 
 
 
 
 
 
- 93 - 
 
               
R
e
la
t
iv
e
 e
x
p
r
e
s
s
io
n
p
F
A
K
 Y
8
6
1
p
F
A
K
 Y
4
0
1
p
F
A
K
 Y
9
2
5
p
F
A
K
 Y
5
7
6
/5
7
7
0
1
2
3
N T  S Y F
S Y F -Y e s
N T  S Y F
S Y F -S rc
                     
Figure 39: Overexpression of Src and Yes kinase in SYF mouse embryonic fibroblasts. 
SYF MEF cells were transfected with PCDNA3.1 Src, pCMV6XL5-Yes and NT control 
plasmids for 24 hours and the cells were trypsinized and lysed after 48 hours of transfection. 
Cell lysates were subjected to immunoblot analyses for expression of Src and pFAK. Relative 
protein expression was determined after normalization to vinculin using NIH ImageJ. 
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 Yes promotes prostate cancer lymph node metastasis in the orthotopic nude mouse model 
To determine whether Yes overexpression promoted lymph node metastases in nude 
mouse models, intraprostatic injections were performed as described in materials and methods. 
For these experiments, control and Yes silenced cell lines with two different sequences were 
transduced with a plasmid directing luciferase expression. Following orthotopic injections, 
bioluminescence imaging of mice was performed weekly and mice were sacrificed when the 
primary tumors reached similar sizes (Figure 40, 42). A representative image of mice inoculated 
with cell lines expressing each construct is shown in Figure 44. Lymph node metastases were 
formed in all the groups and, with similar sized primary tumors as shown in Figure 40. NT PC3 
Mig-3 cells formed 3.5 ±0.22 lymph node metastasis compared to 1.8± 0.3 lymph node 
metastases in the shYes#1006 group and 1.6± 0.2 lymph node metastases in the shYes#1006 
group, indicated in Figure 41. Therefore, increased Yes expression is associated with prostate 
cancer lymph node metastases. 
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Figure 40: Tumorigenicity assay of PC3 Mig-3 cells after silencing Yes. Primary tumor 
weights after intraprostatic injection of 1X106 NT PC3 Mig-3, shYes #1006 PC3 Mig-3 and 
shYes #1611 PC3 Mig-3 cells. The tumors were grown for 28 days and the mice were 
sacrificed.  
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Figure 41: Tumorigenicity assay of PC3 Mig-3 cells after silencing Yes. Incidence of lymph 
node metastasis after intraprostatic injection of 1X106 NT PC3 Mig-3, shYes #1006 PC3 Mig-
3 and shYes #1611 PC3 Mig-3 cells. The tumors were grown for 28 days and the mice were 
sacrificed. **p<0.001, ***p<0.0001 by ANOVA and Tukey’s test. 
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Figure 42: In vivo growth rate of PC3 Mig-3 cells after silencing Yes. Intraprostatic 
injections were performed using 1X106 NT PC3 Mig-3, shYes#1006 PC3 Mig-3 and 
shYes#1611 PC3 Mig-3 cells. Tumor growth was monitored using luciferase imaging of the 
mice every 3 days after injection. Luciferase counts were calculated by selecting region of 
interests (ROIs) for each mouse. *p<0.005 by Student’s t-test, compared to the control group. 
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Figure 43: Bioluminescence imaging of PC3 Mig-3 cells after silencing Yes using 
luciferase. Representative images from the bioluminescence imaging using luciferase after 
intraprostatic injections were performed using 1X106 NT PC3 Mig-3, shYes#1006 PC3 Mig-3 
and shYes#1611 PC3 Mig-3 cells. The scales for imaging were standardized for each set. 
 
 
 
 
NT PC3 Mig-3 shYes PC3 Mig-3 
- 99 - 
 
 
 
 
 
 
Table 3: Average weight and incidence of lymph node metastasis after knockdown of Yes 
in PC3 Mig-3 cells 
ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, **p<0.001 
  
Group Average 
Tumor wt. 
(mg)/ range 
Incidence 
of primary 
tumor 
Average incidence 
of LN mets/ range 
Incidence of 
LN 
Metastases 
NT PC3 Mig-3 556.7 (490-670) 6/6 3.5 (3-4)** 6/6 
sh Yes #1006 PC3 Mig-3 572.8 (436-694) 6/6 1.8 (1-3) ** 6/6 
sh Yes #1611PC3 Mig-3 604.7 (494-687) 6/6 1.6 (1-3) ** 6/6 
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Figure 44: Representative primary tumors and lymph node metastases when mice were 
sacrificed. Luciferase-labeled NT Control PC3 Mig-3 and shYes PC3 Mig-3 cells (1 × 105) 
were orthotopically injected into the prostate. Mice were sacrificed when primary tumors 
reached similar sizes as monitored by bioluminescence imaging. 
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Chapter-6 
Yes and pFAK Y861 expression in 
human prostate cancer 
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To determine the clinical relevance of pFAK Y861 and Yes expression in prostate 
cancer lymph node metastasis, I performed immunohistochemical analysis on formalin-fixed 
human prostate tumor specimens. 
Correlation of pFAK Y861 expression in human prostate cancer patient specimens to survival 
To examine the association of pFAK Y861 with patient survival, I collaborated with Dr. 
Chien-Jui Cheng and Dr. Sue-Hwa Lin. We examined pFAK Y861 expression in lymph node 
metastases of prostate cancer patients. The pFAK Y861 antibody was validated using a negative 
control experiment without the primary antibody. Patients were scored for positive (<10% of 
pFAK Y861 positive cells) and negative staining (>10% of pFAK Y861 positive cells) for 
pFAK Y861 expression. Representative images of lymph node metastases are shown in Figure 
46. Patients with positive pFAK Y861 expression had an overall survival 6.13 ±0.99 years. In 
contrast patients with negative pFAK Y861 expression), had an overall survival of 11.69±1.67 
years, (p=0.008) as represented in Figure 46. These data indicate that high expression of pFAK 
Y861 in prostate cancer patients correlate with poor survival. 
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Figure 45: pFAK Y861 expression in lymph node metastases in human prostate cancer 
Immunohistochemical staining of pFAK Y861 in lymph node metastases.  
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Figure 46: Survival analysis of patients with or without expression of pFAK Y861. The 
average survival time of cases with FAKpY861 expression is 6.13±0.99 years and in contrast, 
the average survival time of cases without FAKpY861 expression is 11.69±1.67 years. p=0.008 
(logrank). 
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Yes expression in human prostate cancer patient specimens 
To examine Yes kinase expression in prostate cancer primary tumors and matching 
lymph node metastases using a Yes-specific antibody, we obtained human prostate cancer 
primary tumor and lymph node metastases samples from the prostate cancer tissue bank at M. 
D. Anderson Cancer Center, under an approved IRB protocol. The Yes antibody was validated 
for specific staining by using a negative control experiment without using the primary antibody. 
Representative images of primary tumors and lymph node metastases are shown in Figure 47. 
We used 10 matching sample sets of primary tumors and lymph node metastases for the 
analysis. Yes expression was detected in all primary tumors and lymph node metastases. In 
addition, high expression was observed in lymphocytes. Average intensity of Yes expression 
was calculated after DAB extraction from each sample as described by Park et al. [114]. Yes 
expression in lymph node metastases in each set was significantly higher than the matching 
primary tumors (p<0.05-p<0.00005), indicated by the matching colors in the graph (Figure 48). 
The ratio of Yes expression in the primary tumor to its matching lymph node metastasis was 
determined. As shown in Figure 49, Yes expression was increased by 3.2-fold (p<0.005) in the 
lymph node metastases relative to the matching primary tumors, similar to what we observed 
in the PC3 Mig-3 and DU145 Mig-3 cells versus the parental prostate cancer cells.  
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Figure 47: Yes expression in primary tumors and lymph node metastases in human 
prostate cancer. Immunohistochemical staining of Yes in primary tumor, lymph node 
metastases and matching H&E staining indicating the presence of tumor. The brown DAB 
staining indicates membranous localization of Yes kinase. 
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Figure 48: Quantification of Yes expression in primary tumors and lymph node 
metastases from human prostate cancer specimens. The graph represents average ratio of 
Yes expression in primary tumor to the matching lymph node metastasis. Similar color sets 
indicate matching lymph node metastasis has significantly higher Yes expression relative to 
primary tumors. * p<0.05, **p<0.005, **p<0.0005 by Student’s t-test, compared to the control 
group. 
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Chapter-7 
Discussion 
 
 
  
- 109 - 
 
Metastasis is the cause of mortality in the majority of prostate cancer patients. Because 
signature genetic alterations in prostate cancer are rare, understanding regulation of key gene 
products associated with metastasis, such as aberrant expression and activity of protein tyrosine 
kinases, is critical for prostate cancer progression. Activation of integrins and growth factor 
receptors result in activation of the FAK-SFK pathway, which is associated with increased 
migration and metastasis of prostate cancer cells. Additionally, in prostate cancer several 
pathways downstream of FAK are also activated, indicating that FAK is one of the central 
mediators of prostate cancer progression. FAK is overexpressed in metastasis but mutations in 
FAK are not found in human tumors and few if any studies have determined whether alterations 
in FAK either expression or phosphorylation are truly critical to metastasis. Since, FAK 
inhibitors are in clinical trials, understanding how FAK regulates metastasis of prostate cancer 
is critical. Hence, I investigated FAK and key elements that regulate FAK to understand its 
potential role in processes critical to metastasis.  
Classical activation of FAK occurs after integrin clustering or growth factor receptor 
activation resulting in autophosphorylation of FAK Y397 and recruitment of SFKs [92]. The 
activated FAK-SFK complex then phosphorylates FAK Y401, FAK Y576, FAK Y577, FAK 
Y861 and FAK Y925. Phosphorylation of FAK at the SFK-dependent tyrosine residues 
discussed above, are known to be equivalent and the role of preferential phosphorylation of the 
FAK tyrosine residues in prostate cancer progression is unknown. Previous studies indicate that 
Src phosphorylates FAK in vitro [133] and other members of the Src family kinase are predicted 
to phosphorylate FAK similarly, however, the role of the different SFKs in regulation of FAK 
has not been investigated extensively. Hence, understanding the roles of individual SFKs in 
FAK phosphorylation is important, because increased expression of Src, Lyn and Fyn kinase, 
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the SFKs are all associated with prostate cancer progression [100, 107, 113, 115, 127].  
However, Yes, also known to be expressed in prostate cancer has received much less attention.    
Selection of highly migratory variants of prostate cancer cells 
  To understand the role of FAK in migration and metastasis of prostate cancer, and 
possible unique roles for SFKs in regulating FAK, I established cell models that specifically 
selected for isogenic variants with increased migration. While, in prior studies by other 
investigators, several isogenic cell lines had been isolated from mice with increased metastatic 
potential [134, 135], I selected cells through a Boyden chamber with the intent of specifically 
focusing on migration, to better understand specifically how FAK and FAK-SFK complexes 
that regulate this process. Surprisingly, the migration selection of cells selected for additional 
metastatic properties including increased invasion, decreased adhesion, and decreased 
proliferation in PC3 Mig-3 and DU145 Mig-3 cells relative to the parental cells. These data led 
me to examine the in vivo metastatic ability of PC3 Mig-3 cells in the orthotopic nude mode 
model for prostate cancer. I found that PC3 Mig-3 tumors had increased lymph node metastases 
relative to the PC3-P tumors confirming that migration selection of prostate cancer cells leads 
to selection of more metastatic cells that further highlighted the roles of the FAK/SFK signaling 
pathways. It is likely that this occurred because the parental PC3 cells that were used for 
selection of the PC3 Mig-3 cells are inherently metastatic. However, it is seems unlikely that 
this selection strategy would isolate a highly metastatic cell line from a non-tumorigenic 
immortalized line. Future studies could be to attempt this selection strategy in an immortalized 
non-tumorigenic cell line such as RWPE, to see if similar changes in FAK occurred, and which 
properties are altered due to the migration selection. This type of selection would seem unlikely 
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to increase all the properties I examined associated with metastasis, and may provide 
information as to the molecular alterations in earlier stages of prostate cancer progression. 
Increased phosphorylation of FAK Y861 is a critical alteration associated with more 
migratory PC3 Mig-3 and DU145 Mig-3 cells. 
Since we established two highly migratory cell models with increased metastatic 
potential, I next examined the alterations in FAK-SFK complexes that could be associated with 
the PC3 Mig-3 and DU145 Mig-3 cells. Classical activation of FAK requires 
autophosphorylation of FAK Y397 leading to phosphorylation of the remaining tyrosine sites 
on FAK. However, I found that in the highly migratory PC3 Mig-3 and DU145 Mig-3 cells, 
that only phosphorylation of FAK Y861 was increased independent of phosphorylation of FAK 
Y397, FAK Y401, FAK Y577, FAK Y576, and FAK Y925. Hence, I focused on understanding 
the role of increased phosphorylation of FAK Y861 in migration and metastasis of prostate 
cancer cells, discussed in the next sections. Interestingly, the total levels of FAK remained 
unaltered. This was an unexpected result given increases in FAK expression is observed in 
human prostate cancer metastases [126]. This leads to the question of whether overexpression 
of FAK leads to an increase in the number of FAK molecules phosphorylated, and therefore the 
phosphorylation, not the expression may be important in prostate cancer metastasis. This could 
be tested by overexpressing FAK in a low metastatic cell lines or in a genetically engineered 
mouse model that overexpresses FAK and then examining the levels of phosphorylated FAK 
Y861 along with the biological changes associated with increased FAK expression. 
Additionally, recent data also suggests that nuclear FAK functions as a transcription factor [136] 
, and whether this function is associated with tumor progression and metastasis would be an 
important question to address.   
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To directly test whether pFAK Y861 regulates migration of PC3 Mig-3 cells, we 
overexpressed the non-phosphorylatable FAK Y861F mutant in the PC3 Mig-3 cells using a 
lentiviral expression vector. Migration assays indicated that inhibition of phosphorylation of 
FAK Y861 lead to decreased migration of PC3 Mig-3 cells. Previous studies have indicated that 
phosphorylation of FAK Y861 is associated with migration of fibroblasts [93]; however no 
cause/effect relationship was established. Our studies have indicated that highly migratory 
prostate cancer cell lines may specifically increase phosphorylation of FAK Y861 and this 
might be important in FAK-mediated migration of cells. 
To further, investigate the role of pFAK Y861 in prostate cancer metastasis, I examined 
pFAK Y861 expression in primary tumor and lymph node metastases, and I found a significant 
increase in expression of pFAK Y861 in the lymph node metastases relative to the primary 
tumors in the parental PC3 cells. These data indicate that similar to the in vitro selection, PC3-
P cells with high expression of pFAK Y861 were selected to form lymph node metastasis with 
increased expression of pFAK Y861. On the contrary, PC3 Mig-3 primary tumors had high 
expression of pFAK Y861 and there was no further increase in pFAK Y861 in PC3 Mig-3 
lymph node metastasis. This could be occurring as pFAK Y861 might be maximally activated 
in the PC3 Mig-3 primary tumors leading to increased lymph node metastasis in this group. 
These data confirm that pFAK Y861 expression is associated with metastasis of prostate cancer 
cells. 
Previous studies from our laboratory have indicated that alterations in several other 
oncogenic proteins including Axl and Met are also associated with increased migration and 
metastasis of prostate cancer cells [131], and it was possible that these RTKs contributed to the 
increased phosphorylation of FAK Y861. Hence, I further investigated the role of Axl and Met 
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in PC3 Mig-3 cells in Chapter 4. Using the subcloning approach, I demonstrate that that in spite 
of increased expression of Axl and Met in the uncloned population of PC3 Mig-3 cells, 
subclones of the same cell line had differential expression of Axl, Met, and the only consistent 
alteration associated with increased migration of all the subclones was increased 
phosphorylation of FAK Y861. These data indicated that increased phosphorylation of FAK 
Y861 is a critical phenomenon occurring downstream of Axl and Met signaling. Our results 
suggest that Axl and Met could play a less dominant role in migration than the FAK-SFK 
complexes later in tumor progression, after cells have become metastatic. A better 
understanding of the roles of Met and Axl might require using cell lines lacking the ability to 
metastasize, in which their expression can be genetically manipulated. In line with these 
observations, work from our laboratory has shown that knockdown of Met in patient-derived 
xenografts from late-stage castrate resistant prostate cancer patients does not affect tumor 
growth, suggesting that Met-mediated effects may be at an earlier stage of progression than I 
studied. This possibility could be further analyzed by overexpression of Axl and Met in non-
metastatic cells or in cells with lower intrinsic metastatic potential than I used in my thesis.     
Yes is overexpressed and has increased activity in migratory cells relative to parental 
prostate cancer cells 
To examine the mechanism of increased phosphorylation of FAK Y861, I investigated 
Src family kinases (SFKs), which are the principal kinases that phosphorylate FAK. SFKs are 
recruited to the phosphorylated tyrosine 397 of FAK via the SH2-SFK domain after activation 
and subsequently the FAK-SFK complex phosphorylates the remaining tyrosine residues of 
FAK. Although in vitro studies indicate that Src phosphorylates FAK [133], less is known about 
the role of other SFK members in FAK-mediated functions. As discussed in the introduction, 
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SFKs have structural and functional similarities; however, studies have identified different roles 
of SFKs in in prostate cancer progression [113, 116, 122, 127]. Hence, I examined the 
expression levels of the SFK members in PC3 Mig-3 cells. The data indicated that only Yes 
kinase was overexpressed and had increased activity in the PC3 Mig-3 and DU145 Mig-3 cells 
relative to the parental cells at both protein and RNA levels. Additionally, our previous data 
from the subcloning (Figure 21) indicated that increased expression of Yes kinase was a 
consistent alteration. This correlates with increased transcription of Yes. The mechanism by 
which transcription leads to overexpression of Yes in my migratory variants were increased was 
not addressed in this thesis. However, the cDNA array studies performed in collaboration with 
Dr. Woonyoung Choi and Dr. David McConkey indicated increased expression of several 
transcription factors such as c-MYC, FOXA1 and HEY1 in the PC3 Mig-3 cells relative to the 
parental cells. These transcription factors have binding sites on the Yes promoter and could be 
important in upregulating transcription of Yes (Figure 52).  
The reasoning behind why selection of highly migratory cells also had increased 
expression and activity of Yes is also unknown. However I speculate that overexpression and 
over activity Yes kinase in the more migratory cells could be because that the other SFKs are 
close to maximally activated; and the specific migration selection selected for only the cells that 
had increased Yes activity required for preferential phosphorylation of pFAK Y861 and 
migration. Future studies could be to perform other selections for additional metastatic 
properties such as for adhesion, proliferation, or anoikis and examine whether alterations 
associated with other SFKs exist. 
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Yes preferentially phosphorylates FAK Y861 in PC3 Mig-3 cells 
To directly investigate whether Yes phosphorylates FAK Y861, I first silenced the 
expression of Yes kinase in PC3 Mig-3 cells. Knockdown of Yes in the PC3 Mig-3 cells, 
preferentially downregulated pFAK Y861 expression and to some extent pFAK Y925 
expression indicating that Yes specifically regulates both pFAK Y861 and pFAK Y925 in the 
PC3 Mig-3 model. Likewise, overexpression of Yes in PC3-P cells led to increased pFAK Y861 
and pFAK Y925 expression. However, while Yes preferentially phosphorylated FAK Y861 and 
FAK Y925, the role of Src in phosphorylation of FAK in PC3 Mig-3 cells was not preferential 
to FAK Y861 and FAK Y925. I demonstrated that knockdown of Src in PC3 Mig-3 led to 
decreased phosphorylation of all the SFK-dependent FAK tyrosine sites and overexpression of 
Src lead to increased phosphorylation of all the SFK-dependent FAK tyrosine sites. I speculate 
that this Yes-mediated preferential phosphorylation of FAK Y861 and FAK Y925 in PC3 Mig-
3 occurs because only Yes was overexpressed and had increased activity in PC3 Mig-3 cells 
relative to the parental cells. Additionally, previous reports indicate that Yes has weaker specific 
kinase activity against exogenous enolase relative to Src kinase in colorectal cancer cells [137], 
potentially explaining selective phosphorylation of only FAK Y861 and FAK Y925. 
Interestingly, FAK Y925 has also been associated with migration, and many of the signaling 
pathways activated through FAK Y861 phosphorylation are activated through FAK Y925 
phosphorylation as well. So it is even more interesting that Yes also affects FAK Y925, further 
implicating its role in migration. It is unclear why the original selection did not change FAK 
Y925 phosphorylation. I speculate that other activating SFKs may have maximally 
phosphorylated this tyrosine residue and hence, increase in Yes activity after migration 
selection in PC3 cells did not further increase pFAK Y925 levels. Overlapping regulation of 
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pFAK Y861 and pFAK Y925 by Yes kinase is likely to occur due to easy accessibility of Yes 
kinase to these tyrosine residues as both FAK Y861 and FAK Y925 are present on the FAT 
domain of FAK that interacts with additional proteins that form the focal adhesion complex. 
Nevertheless, the role of pFAK Y925 in metastasis of prostate cancer cells could be investigated 
in the future using site-directed mutagenesis of pFAK Y925 in PC3 Mig-3 cells. 
In spite of confirming the role in phosphorylation of FAK Y861 using Yes 
overexpression and Yes knockdown experiments, I could not negate the role of the remaining 
SFK members in phosphorylation of FAK Y861 and FAK Y925 in the PC3 Mig-3 cells. Hence, 
I used the SYF (Src-/-, Yes-/-, Fyn-/-) mouse embryonic fibroblasts model to demonstrate that 
overexpression of Yes kinase in the SYF MEF cells led to increased expression of only pFAK 
Y861 and pFAK Y925. However, overexpression of Src kinase led to equivalent overexpression 
of all the SFK-dependent of FAK phospho-tyrosine sites (Y401, Y577, Y576, Y861 and Y925), 
consistent with the PC3 cells. Additionally pFAK Y925 is also critically associated with FAK-
mediated migration pathways, so despite the failure of the selection to increase FAK Y925 
phosphorylation, these data suggests that increased Yes might be critical in regulating 
migration.   
Yes-mediated migration of PC3 Mig-3 cells 
Since, increased Yes expression and activity specifically phosphorylated pFAK Y861 
that is associated with the highly migratory PC3 Mig-3 cells, I hypothesized that Yes promotes 
migration in prostate cancer cells. To test this hypothesis, I performed migration assays on PC3 
Mig-3 and PC3-P cells after silencing and overexpression of Yes respectively. I found that Yes 
knockdown in PC3 Mig-3 cells leads to decreased migration, whereas overexpression of Yes in 
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PC3-P cells leads to increase in migration. I speculate that Yes regulates migration of prostate 
cancer cells by phosphorylation of pFAK Y861 and pFAK Y925, both of which recruit p130 
Cas and Paxillin after phosphorylation leading to downstream pathways that regulate the 
migration signaling [138]. The role of Yes in phosphorylation and activation of these 
downstream signaling pathways mediating migration could be determined in the future by 
examining the expression of phospho p130Cas and phospho paxillin after knockdown and 
overexpression of Yes kinase in the PC3 Mig-3 cells. In Chapter 4 of this thesis, I also 
demonstrate that activation of Rho-A GTPases, which I predict is a possible downstream 
signaling mechanism of pFAK Y861 that regulates migration of PC3 Mig-3 cells. The data 
indicates that Rho-A was significantly more active in PC3 Mig-3 cells relative to the PC3-P 
cells additionally, Rho-A was downregulated in FAK Y861F Mig-3 cells, which had reduced 
migration in vitro (Figure 26). However, the role of Rho-A in migration of PC3 Mig-3 cells still 
remains unclear, and could be cell line dependent [139-141]. Hence, further studies are required 
to determine the role of additional proteins that are involved in regulation of Rho-A downstream 
of pFAK Y861. 
Yes promotes lymph node metastases of prostate cancer cells 
The data from Chapter 4 of this thesis indicate previously unknown roles of Yes kinase 
in prostate progression. Yes expression and activity was associated with increased migration of 
cells, however these data were correlative. To further investigate whether Yes affected 
metastasis in vivo, I performed an in vivo tumorigenicity assay using NT PC3 Mig-3 and shYes 
PC3 Mig-3 cells in the orthotopic nude mouse model for prostate cancer. The data indicated 
that shYes PC3 Mig-3 cells formed significantly fewer lymph node metastases relative to NT 
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PC3 Mig-3 cells similar to PC3-P cells. This provides a strong evidence that the increase in Yes 
was responsible for the increased lymph node metastases observed in the PC3 Mig-3 model.  
Clinical significance of the study 
Finally, to determine if the increased metastasis was a result of Yes expression and was 
relevant to human prostate cancer metastasis, I collaborated with Dr. Sue-Hwa Lin and Dr. 
Chein-Jui Cheng to examine pFAK Y861 expression in human tissues. We demonstrated that 
pFAK Y861 is overexpressed in lymph node metastasis of patients with poor survival (Figure 
48, 49). I further demonstrated the clinical significance of Yes overexpression in prostate cancer 
progression by staining matched primary tumors and lymph node metastasis with antibody 
specific for Yes kinase. Increase in Yes expression in lymph node metastasis relative to the 
primary tumors (Figure 51) indicated that, the lymph node metastasis selected for cells 
overexpressing Yes kinase and I demonstrated that increased expression of Yes kinase was 
associated with prostate cancer lymph node metastasis. Since, very less information regarding 
Yes expression in matched primary tumors and lymph node metastases are currently available 
in The Cancer Genome Atlas (TCGA) databases, further confirmation for increased expression 
of Yes kinase in human prostate cancer progression can be determined by examining Yes 
overexpression at the RNA levels in matched primary and lymph node metastasis. mRNA levels 
of yes in patient samples can be determined after micro dissection of the tumor areas from the 
paraffin embedded tumor tissue and isolation of RNA, followed by RT-qPCR for yes expression 
using specific primers. 
We specifically examined lymph node metastasis from prostate cancer patients as the 
spontaneous metastasis of prostate cancer in the mouse models occurs to the lymph node 
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metastasis. Although, lymph node metastasis is not lethal by itself, clinical studies from several 
institutions have indicated that lymph node metastasis is a poor prognostic factor of progression-
free survival in patients and is critical in prostate cancer progression [142-145]. Whether, 
increased expression of pFAK Y861 and Yes kinase is important in bone metastasis can be 
determined experimentally, by performing intracardiac injections of PC3 Mig-3 and DU145 
Mig-3 cells in the mice and examining whether PC3 Mig-3 cells colonize to the bone. Clinically, 
the significance of increased expression of pFAK Y861 and Yes kinase in bone metastasis of 
prostate cancer can be determined by performing immunohistochemistry to determine the 
expression of pFAK Y861 and Yes in human prostate cancer bone metastasis.  
My study has unexpected clinical relevance, as a recent clinical trial investigating the 
role of Dasatinib, a small molecule inhibitor of SFKs did not show significant improvement in 
overall survival of metastatic castrate resistant prostate cancer patients. I demonstrate that 
increased expression and activity of only Yes kinase and not Src kinase is associated with a 
subset of prostate cancer cells, implicating that Src family kinases could be differentially 
upregulated in prostate cancer patients as well. This could be important as patients with 
upregulation of a specific SFK could respond differently to a pan-SFK inhibitor. Hence, 
stratification of patient cohorts depending of expression of different SFK members might be 
crucial for the success of future SFK inhibitor clinical trials and improvement of patient 
outcomes. 
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Future perspectives 
This dissertation investigated the role of many proteins in prostate cancer metastasis. 
While the role of FAK and Src family kinase have been known to be associated with prostate 
cancer metastasis, my work is the first to identify the role of a specifically pFAK Y861 and Yes 
kinase in prostate cancer metastasis. However, many questions remain to be determined in the 
future.  
In vitro migration selection of prostate cancer cells resulted in selection of cells with 
additional properties of metastasis. However, whether selection of cells using additional 
strategies, for example decreased adhesion, decreased proliferation, or increased anoikis would 
lead to selection of more metastatic cells could be another future study. As Src, Fyn and Lyn 
are known to play different roles in prostate cancer development, less is known regarding the 
role of Yes in this process. The role of Yes in promoting prostate cancer initiation and 
progression can be further examined by developing genetically engineered mouse models that 
overexpress Yes. 
Since, we found increased expression of Yes kinase and pFAK Y861 in prostate cancer 
lymph node metastasis with the latter correlating to poor survival of patients, we can examine 
if increased expression of Yes kinase or pFAK Y861 in primary prostate tumor biopsies 
correlate with poor patient survival. Additionally, understanding whether increased expression 
of Yes and pFAK Y861 correlates with bone metastasis would be critical to investigate the role 
of these proteins in prostate cancer progression. This could be accomplished by 
immunohistochemical analysis of Yes and pFAK Y861 in human prostate cancer bone 
metastasis and by examining whether PC3 Mig-3 cells metastasize to the bone after performing 
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intracardiac injections of PC3 Mig-3 cells. This study could have a potential application of Yes 
and pFAK Y861 as biomarkers to detect prostate cancer progression. 
Another approach towards using Yes and pFAK Y861 as biomarkers could be by 
detecting Yes kinase and phosphorylated FAK Y861 in the circulating tumor cells (CTCs). 
Although, whether Yes or pFAK Y861 are expressed in CTCs is not known, preliminary studies 
in our laboratory using antibodies against pFAK Y861 have indicated that expression of pFAK 
Y861 can be detected in PC3 prostate cancer cells experimentally introduced in mouse blood. 
Therefore, FAK phosphorylation and Yes expression may be a biomarker to predict prognosis 
in patients. 
In spite of promising preclinical studies, the recent failure of dasatinib in a multinational 
phase-3 clinical trial indicates that not all the prostate cancer patients respond to a drug and 
selecting the patients that would respond to therapy is critical for improving overall survival of 
patients. Since, my study indicates different roles of Yes kinase in prostate cancer progression, 
a retrospective analysis of expression of different SFKs in the patients that responded to 
dasatinib and the ones that did not respond could be critical understanding the failure of the 
trial. Collectively, these studies would support my study that indicates that pFAK Y861 and 
Yes expression could not only be drivers of prostate cancer but also biomarkers for metastasis 
of prostate cancer 
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Conclusions 
In this dissertation, I demonstrated that in the highly metastatic PC3 Mig-3 and DU145 
Mig-3 cells, increased pFAK Y861 expression was associated with increased metastasis; 
however, the levels of total FAK remained unchanged. Using a non-phosphorylatable mutant 
of pFAK Y861, I demonstrated that pFAK Y861 is critical for migration of cells. Besides, 
increased phosphorylation of pFAK Y861 in lymph node metastasis of prostate cancer patients 
correlated with poor survival. These data demonstrate importance of pFAK Y861 in prostate 
cancer metastasis. Mechanistically, I demonstrated that specifically Yes kinase is responsible 
for preferential phosphorylation of pFAK Y861, indicating different roles of SFK members in 
phosphorylation of FAK in the highly migratory PC3 Mig-3 cells. Additionally, Yes kinase also 
promoted metastasis in vivo mouse model, directly correlating with its ability to increase 
tyrosine phosphorylation of FAK Y861. Finally, increased Yes kinase in lymph node metastases 
relative to matched primary tumors in human prostate cancer indicates the clinical relevance of 
these findings. In summary, I demonstrated that overexpression of Yes kinase promotes 
migration of prostate cancer cells through Yes-mediated preferential phosphorylation of pFAK 
Y861 (summarized in Figure 53). Therefore, I conclude that pFAK Y861 and Yes could be 
potential targets for development of novel therapies for prostate cancer metastasis. 
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Figure 49: Model for preferential phosphorylation of pFAK Y861 in more migratory PC3 
Mig-3 and DU145 Mig-3 cells. (1) In the parental PC3 and DU145 cells, Src phosphorylates 
all the SFK-dependent tyrosine kinase sites on FAK, (2) In the more migratory PC3 Mig-3 and 
DU145 Mig-3 cells, Yes kinase is over expressed and has increased activity leading to 
increased phosphorylation of FAK Y861 and increased migration of cells. 
 
 
 
(1) (2) 
Parental PC3/DU145 cells PC3 Mig-3/DU145 Mig-3 cells 
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APPENDIX 
Microarray analysis 
RNA was isolated from the cells using the MirVana RNA extraction kit (Ambion/Life 
technologies, Austin,TX, USA). RNA was used for synthesis of biotin-labeled cRNA, using the 
Illumina RNA amplification kit (Ambion/Life Technologies, Austin, TX, USA). RNA purity 
and integrity were measured by NanoDrop ND-1000 and Agilent Bioanalyzer and only high 
quality RNA was used for the cRNA amplification, and then hybridized to Illumina-HT12 
(Illumina, Inc., Hayward, CA, USA) chips. Slides were scanned with Bead Station 500X and 
signal intensities were quantified with GenomeStudio (Illumina, Inc.). Quantile normalization 
in the Linear Models for Microarray Data (LIMMA) package in the R language environment 
was used to normalize the data. BRB ArrayTools version 4.2 developed by National Cancer 
Institute was used to analyze the data as described by Choi et al.[146]. To identify molecular 
subtypes, we subjected the data obtained to unsupervised hierarchical cluster analysis using the 
6700 probes that exhibited expression ratios of at least 2-fold relative to the median gene 
expression level across all samples in at least six samples. p<0.001 with FDR <0.1, 1.5 fold cut-
off was used to determine differentially regulated genes in PC3 Mig-3 and PC3-P cells. To 
visualize gene expression patterns, specific gene expression values, adjusted to a median of 
zero, were used for clustering using Cluster 3.0 and TreeView (Eisen et al., 1998). Functional 
and pathway analyses were performed using Ingenuity Pathway Analysis (IPA) software 
(Ingenuity® Systems, CA), which contains a database for identifying networks and pathways 
of interest in genomic data. 
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Figure 50: Heat-map of the migration and invasion regulating genes. Heat-map indicating 
the most differentially regulated genes that are involved in migration and invasion of cells. 
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Figure 51: IPA pathway analysis. Pathway analysis indicating cellular movement signaling 
pathways as the most significantly altered pathway in the PC3 Mig-3 cells relative to the 
parental cells. p<0.001, False discovery rate <0.1 
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Figure 52: UCSC genome browser analysis of transcription factors binding to yes 
promoter. UCSC genome browser analysis indicating binding of several transcription factors 
including HEY1, FOXA1 and c-MYC to the Yes promoter region. 
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G-LISA Rho-A activation assay protocol
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